<TABLE>
<CAPTION>
<S> <C> <C>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 1999
SUGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-24814 13-3629196
(State or other jurisdiction of (Commission File No.) (IRS Employer Identification No.)
incorporation)
230 East Grand Avenue
South San Francisco, CA 94808
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 553-8300
</TABLE>
<PAGE>
Item 5. Other Events.
On June 15, 1999, SUGEN, Inc., a Delaware corporation (the "Company"), entered
into an Agreement and Plan of Merger (the "Merger Agreement") with Pharmacia &
Upjohn, Inc., a Delaware corporation ("Parent"), and University Acquisition
Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Merger
Subsidiary").
Subject to the terms and conditions of the Merger Agreement, Merger Subsidiary
will be merged with and into the Company (the "Merger") at the effective time of
the Merger, and the Company will become a wholly owned subsidiary of Parent. At
the effective time of the Merger, the outstanding shares of common stock, $.01
par value per share, of the Company ("Company Common Stock"), other than shares
of Company Common Stock to be canceled in accordance with the Merger Agreement,
will be converted into the right to receive that number of shares (the "Exchange
Ratio") of common stock, par value $.01 per share, of Parent ("Parent Common
Stock"), based on the average (rounded to the 1/10,000, or if there shall not be
a nearest 1/10,000, to the next highest 1/10,000) of the volume weighted
averages (rounded to the 1/10,000, or if there shall not be a nearest 1/10,000,
to the next highest 1/10,000) of the trading prices of Parent Common Stock on
the New York Stock Exchange, Inc. ("NYSE"), as reported by Bloomberg Financial
Markets for each of the 20 NYSE trading days ending on and including the third
trading day immediately preceding the meeting of stockholders of the Company
called to vote on the Merger (the "Average Price"), determined as follows:
(i) if the Average Price is greater than $49.21875 and less than
$60.15626, then the Exchange Ratio shall equal $31.00 divided by the
Average Price;
(ii) if the Average Price is equal to or less than $49.21875, then the
Exchange Ratio shall equal 0.62984; or
(iii) if the Average Price is equal to or greater than $60.15625, then
the Exchange Ratio shall equal 0.51533.
In addition, Parent will assume outstanding options exercisable for Company
Common Stock.
The Merger is intended to be a tax-free reorganization under the Internal
Revenue Code of 1986, as amended, and is intended to be accounted for as a
pooling-of-interests. The Merger is subject to approval by the stockholders of
the Company, regulatory approvals and other customary closing conditions.
Also on June 15, 1999, the Company entered into a Stock Option Agreement with
Parent (the "Stock Option Agreement") pursuant to which the Company granted an
option to Parent to purchase up to 3,372,255 shares of Company Common Stock at a
price of $31.00 per share upon the occurrence of certain events related to
termination of the Merger Agreement. In addition, certain affiliates of the
Company entered into voting agreements on June 15, 1999, pursuant to which such
affiliates agreed to vote shares owned by them in favor of the Merger.
The foregoing summaries of certain principal terms of the Merger Agreement and
the Stock Option Agreement do not purport to be complete and are qualified in
their entirety by reference to the Merger Agreement and the Stock Option
Agreement, copies of which are attached hereto as Exhibit 2.1 and Exhibit 2.2,
respectively, and are hereby incorporated by reference herein.
<PAGE>
A copy of the press release issued by Parent and the Company on June 15, 1999 is
attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein.
A registration statement relating to the Parent Common Stock to be issued in
connection with the Merger has not yet been filed with the SEC, nor has a proxy
statement relating to a vote of the Company's stockholders on the Merger been
filed with the SEC. The Parent Common Stock may not be offered, nor may offers
to acquire such stock be accepted, prior to the time such a registration
statement becomes effective. This Report shall not constitute an offer to sell
or the solicitation of an offer to buy any Parent Common Stock or any other
security, and shall not constitute the solicitation of any vote with respect to
the Merger.
This Current Report on Form 8-K contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The forward-looking
statements contained herein involve risks and uncertainties, including those
relating to the possible inability to complete the merger transaction involving
the Company and Parent as scheduled, if at all, and those associated with the
ability of the combined company to achieve the anticipated benefits of the
merger. Actual results and developments may differ materially from those
described or incorporated by reference in this Report. For more information
about Parent and the Company and risks arising when investing in Parent and the
Company, investors are directed to Parent's and the Company's most recent report
on Form 10-K and most recent report on Form 10-Q as filed with the Securities
and Exchange Commission (the "SEC").
Item 7. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
Not applicable.
(b) Pro forma financial information.
Not applicable.
(c) Exhibits
2.1 Agreement and Plan of Merger, dated June 15, 1999, by and
among Pharmacia & Upjohn, Inc., a Delaware corporation
("Parent"), University Acquisition Corp., a Delaware
corporation, and SUGEN, Inc., a Delaware corporation (the
"Company").
2.2 Stock Option Agreement, dated June 15, 1999, by and between
Parent and the Company.
99.1 Joint Press Release of Parent and the Company, issued June 15,
1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SUGEN, INC.
/s/ James L. Knighton
----------------------------------------------
By: James L. Knighton
Senior Vice President and Chief Financial
Officer
Dated: June 17, 1999
<PAGE>
Exhibit
Number Exhibit Description
- ------- -------------------
2.1 Agreement and Plan of Merger, dated June 15, 1999, by and
among Pharmacia & Upjohn, Inc., a Delaware corporation
("Parent"), University Acquisition Corp., a Delaware
corporation and SUGEN, Inc., a Delaware corporation (the
"Company").
2.2 Stock Option Agreement, dated June 15, 1999, by and between
Parent and the Company.
99.1 Joint Press Release of Parent and the Company.
EXHIBIT 2.1
EXECUTION COPY
AGREEMENT AND PLAN OF MERGER
among
SUGEN, INC.,
PHARMACIA & UPJOHN, INC.
and
UNIVERSITY ACQUISITION CORP.
Dated as of June 15, 1999
<PAGE>
Table of Contents
-----------------
Section Page
- ------- ----
ARTICLE I
The Merger; Closing; Effective Time
1.1. The Merger..........................................................2
1.2. Closing.............................................................2
1.3. Effective Time......................................................3
ARTICLE II
Certificate of Incorporation
and Bylaws of the Surviving Corporation
2.1. The Certificate of Incorporation....................................3
2.2. The Bylaws..........................................................3
ARTICLE III
Officers and Directors
of the Surviving Corporation
3.1. Directors...........................................................3
3.2. Officers............................................................4
ARTICLE IV
Effect of the Merger on Capital Stock;
Exchange of Certificates
4.1. Effect on Capital Stock.............................................4
(a) Merger Consideration............................................4
(b) Cancellation of Excluded Shares.................................5
(c) Merger Sub......................................................5
4.2. Exchange of Certificates for Shares.................................6
(a) Exchange Agent..................................................6
(b) Exchange Procedures.............................................6
(c) Distributions with Respect to Unexchanged Shares; Voting........7
(d) Transfers.......................................................8
(e) Fractional Shares...............................................8
(f) Termination of Exchange Fund....................................9
(g) Lost, Stolen or Destroyed Certificates..........................9
4.3. Dissenters' Rights..................................................9
-i-
<PAGE>
Section Page
- ------- ----
4.4. Adjustments to Prevent Dilution....................................10
4.5. Treatment of Convertible Notes.....................................10
ARTICLE V
Representations and Warranties
5.1. Representations and Warranties of the Company......................10
(a) Organization, Good Standing and Qualification.................10
(b) Capital Structure.............................................12
(c) Corporate Authority; Approval and Fairness....................14
(d) Governmental Filings; No Violations...........................15
(e) Company Reports; Financial Statements.........................17
(f) Absence of Certain Changes....................................18
(g) Litigation and Liabilities....................................19
(h) Employee Benefits.............................................19
(i) Compliance....................................................22
(j) Antitakeover Statutes.........................................23
(k) Environmental Matters.........................................23
(l) Accounting and Tax Matters....................................25
(m) Taxation......................................................25
(n) Certain Regulatory Matters....................................27
(o) Intellectual Property.........................................29
(p) Product Registration Files....................................33
(q) Year 2000 Compliance..........................................34
(r) Labor Matters.................................................34
(s) Rights Agreement..............................................34
(t) Brokers and Finders...........................................35
(u) Supply Arrangements...........................................35
(v) Investigational Compounds.....................................35
5.2. Representations and Warranties of Parent and Merger Sub............36
(a) Capitalization of Merger Sub...................................36
(b) Organization, Good Standing and Qualification..................36
(c) Capital Structure..............................................37
(d) Corporate Authority............................................38
(e) Governmental Filings; No Violations............................39
(f) Parent Reports; Financial Statements...........................40
(g) Absence of Certain Changes.....................................41
(h) Litigation and Liabilities.....................................41
(i) Compliance.....................................................42
(j) Accounting and Tax Matters.....................................42
(k) Brokers and Finders............................................42
-ii-
<PAGE>
Section Page
- ------- ----
ARTICLE VI
Covenants
6.1. Company Interim Operations.........................................43
6.2. Conduct of Business of Parent......................................46
6.3. Acquisition Proposals..............................................47
6.4. Information Supplied...............................................50
6.5. Stockholders Meeting...............................................50
6.6. Filings; Other Actions; Notification...............................51
6.7. Taxation and Accounting............................................55
6.8. Access.............................................................57
6.9. Affiliates.........................................................58
6.10. Listing; De-registration...........................................59
6.11. Publicity..........................................................59
6.12. Benefits...........................................................60
(a) Stock Options..................................................60
(b) Employee Benefits..............................................61
6.13. Expenses...........................................................61
6.14. Indemnification; Directors' and Officers' Insurance................62
6.15. Other Actions by the Company and Parent............................64
(a) Rights .......................................................64
(b) Antitakeover Statutes..........................................64
6.16. Convertible Notes and Warrants.....................................64
6.17. Funding Mechanism..................................................64
ARTICLE VII
Conditions
7.1. Conditions to Each Party's Obligation to Effect the Merger.........66
(a) Stockholder Approval...........................................66
(b) Regulatory Consents............................................66
(c) Litigation.....................................................66
(d) Registration Statement.........................................67
7.2. Conditions to Obligations of Parent and Merger Sub.................67
(a) Representations and Warranties.................................67
(b) Performance of Obligations of the Company......................68
(c) Regulatory Consents............................................68
(d) Consents Under Agreements......................................68
(e) Tax Opinion....................................................69
-iii-
<PAGE>
Section Page
- ------- ----
(f) Rights Agreement...............................................69
(g) Affiliates Letters.............................................69
(h) Accountants' Letters...........................................69
7.3. Conditions to Obligation of the Company............................69
(a) Representations and Warranties.................................69
(b) Performance of Obligations of Parent and Merger Sub............70
(c) Regulatory Consents............................................70
(d) Tax Opinion....................................................71
(e) NYSE Listing...................................................71
(f) Accountants' Letters...........................................71
ARTICLE VIII
Termination
8.1. Termination by Mutual Consent......................................71
8.2. Termination by Either Parent or the Company........................71
8.3. Termination by the Company.........................................72
8.4. Termination by Parent..............................................73
8.5. Effect of Termination and Abandonment..............................74
ARTICLE IX
Miscellaneous and General
9.1. Survival...........................................................77
9.2. Modification or Amendment..........................................77
9.3. Waiver of Conditions...............................................77
9.4. Counterparts.......................................................77
9.5. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL......................77
9.6. Notices............................................................79
9.7. Entire Agreement...................................................80
9.8. No Third Party Beneficiaries.......................................80
9.9. Obligations of Parent and of the Company...........................80
9.10. Severability.......................................................81
9.11. Specific Performance...............................................81
9.12. Interpretation.....................................................81
9.13. Assignment.........................................................81
9.14. Captions...........................................................82
-iv-
<PAGE>
AGREEMENT AND PLAN OF MERGER (hereinafter called this
"Agreement"), dated as of June 15, 1999, among SUGEN, Inc., a Delaware
corporation (the "Company"), Pharmacia & Upjohn, Inc., a Delaware corporation
("Parent"), and University Acquisition Corp., a Delaware corporation and a
wholly owned subsidiary of Parent ("Merger Sub," the Company and Merger Sub
sometimes being hereinafter collectively referred to as the "Constituent
Corporations").
RECITALS
WHEREAS, the respective boards of directors of each of Parent,
Merger Sub and the Company have approved the merger of Merger Sub with and into
the Company (the "Merger") and approved the Merger upon the terms and subject to
the conditions set forth in this Agreement and have determined that the Merger
and the other transactions contemplated by this Agreement are fair to, and in
the best interest of, their respective stockholders;
WHEREAS, it is intended that, for federal income tax purposes,
the Merger shall qualify as a reorganization under the provisions of Section
368(a) of the Internal Revenue Code of 1986, as amended, and the rules and
regulations promulgated thereunder (the "Code");
WHEREAS, for financial accounting purposes, it is intended
that the Merger shall be accounted for as a "pooling-of-interests;"
WHEREAS, contemporaneously with the execution and delivery of
this Agreement, the Company is entering into a stock option agreement with
Parent (the "Stock Option Agreement"), pursuant to which the Company has granted
to Parent an option to purchase Shares (as defined in Section 4.1(a)) under the
terms and conditions set forth in the Stock Option Agreement; and
WHEREAS, contemporaneously with the execution and delivery of
this Agreement, certain holders of Shares are entering into a voting agreement
with Parent (the "Voting Agreement") pursuant to which such holders have made
certain agreements with respect to the Shares held by them.
NOW, THEREFORE, in consideration of the premises, and of the
representations, warranties, covenants and agreements contained herein and in
the Stock Option Agreement, the parties hereto agree as follows:
<PAGE>
ARTICLE I
The Merger; Closing; Effective Time
1.1. The Merger. Upon the terms and subject to the conditions
set forth in this Agreement, at the Effective Time (as defined in Section 1.3)
Merger Sub shall be merged with and into the Company and the separate corporate
existence of Merger Sub shall thereupon cease. The Company shall be the
surviving corporation in the Merger (sometimes hereinafter referred to as the
"Surviving Corporation") and shall continue to be governed by the laws of the
State of Delaware, and the separate corporate existence of the Company with all
its rights, privileges, immunities, powers and franchises shall continue
unaffected by the Merger, except as set forth in Articles II and III. The Merger
shall have the effects specified in the Delaware General Corporation Law, as
amended (the "DGCL"). Parent, as the sole stockholder of Merger Sub, hereby
approves the Merger and this Agreement.
1.2. Closing. The closing of the Merger (the "Closing") shall
take place (i) at the offices of Sullivan & Cromwell, 125 Broad Street, New
York, New York at 10:00 a.m. on the latest to occur of (A) the business day on
which the condition set forth in Section 7.1(a) shall be satisfied or waived in
accordance with this Agreement and (B) the first business day following the date
on which the last to be satisfied or waived of the other conditions set forth in
Article VII (other than those conditions that by their nature are to be
satisfied at the Closing, but subject to the satisfaction or waiver of those
conditions) shall be satisfied or waived in accordance with this Agreement, or
(ii) at such other place and time and/or on such other date as the Company and
Parent may agree in writing (the "Closing Date").
1.3. Effective Time. As soon as practicable following the
Closing, the Company will cause a Certificate of Merger (the "Certificate of
Merger") to be executed, acknowledged and filed with the Secretary of State of
Delaware as provided in Section 251 of the DGCL. The Merger shall become
effective at the time when the Certificate of Merger has been duly filed with
the Secretary of State of the State of Delaware or, if agreed to by Parent and
the
-2-
<PAGE>
Company, such later time or date set forth in the Certificate of Merger (the
"Effective Time").
ARTICLE II
Certificate of Incorporation
and Bylaws of the Surviving Corporation
2.1. The Certificate of Incorporation. The certificate of
incorporation of Merger Sub as in effect immediately prior to the Effective Time
shall be the certificate of incorporation of the Surviving Corporation (the
"Charter"), except that Article FIRST of the Charter shall be amended to read in
its entirety as follows: "The name of the corporation is SUGEN, Inc."
2.2. The Bylaws. The bylaws of Merger Sub in effect
immediately prior to the Effective Time shall be the bylaws of the Surviving
Corporation (the "Bylaws"), until thereafter amended as provided therein or by
applicable law.
ARTICLE III
Officers and Directors
of the Surviving Corporation
3.1. Directors. The directors of Merger Sub immediately prior
to the Effective Time shall, from and after the Effective Time, be the directors
of the Surviving Corporation until their successors have been duly elected or
appointed and qualified or until their earlier death, resignation or removal in
accordance with the Charter and Bylaws. Prior to the Effective Time, the Company
shall take all actions necessary to obtain any resignations of its directors
necessary to give effect to the provisions of this Section.
3.2. Officers. The officers of the Company immediately prior
to the Effective Time shall, from and after the Effective Time, be the officers
of the Surviving Corporation until their successors have been duly elected or
appointed and qualified or until their earlier death, resignation or removal in
accordance with the Charter and Bylaws.
-3-
<PAGE>
ARTICLE IV
Effect of the Merger on Capital Stock;
Exchange of Certificates
4.1. Effect on Capital Stock. At the Effective Time, as a
result of the Merger and without any action on the part of the Company, Parent,
Merger Sub or any holder of any capital stock of the Company:
(a) Merger Consideration. (i) Each share of common stock, par
value $0.01 per share, of the Company (each a "Share" or, collectively, the
"Shares") issued and outstanding immediately prior to the Effective Time (other
than Shares owned by Parent or any direct or indirect Subsidiary of Parent
(collectively, the "Parent Companies") or Shares that are owned by the Company
or any direct or indirect Subsidiary of the Company (and in each case not held
on behalf of third Parties)("Excluded Shares")) shall, subject to Section
4.2(e), be converted into, and become exchangeable for the right to receive (the
"Merger Consideration") that number of shares (the "Exchange Ratio") of common
stock, par value $0.01 per share (the "Parent Common Stock"), of Parent
determined by dividing $31.00 by the Average Price (as defined below); provided,
that (A) if the Average Price is equal to or less than $49.21875, the Exchange
Ratio shall be .62984; and (B) if the Average Price is equal to or greater than
$60.15625, the Exchange Ratio shall be .51533. "Average Price" means the average
(rounded to the nearest 1/10,000, or if there shall not be a nearest 1/10,000,
to the next highest 1/10,000) of the volume weighted averages (rounded to the
nearest 1/10,000, or if there shall not be a nearest 1/10,000, to the next
highest 1/10,000) of the trading prices of Parent Common Stock on the New York
Stock Exchange, Inc. (the "NYSE") as reported by Bloomberg Financial Markets (or
such other source as the parties shall agree in writing) for each of the NYSE
Trading Days; and (ii) "NYSE Trading Days" means the 20 NYSE trading days ending
on (and including) the third trading day immediately preceding the Stockholders
Meeting (as defined in Section 6.5).
(ii) At the Effective Time, all Shares shall no longer be
outstanding and shall be canceled and retired and shall cease to exist, and each
certificate (a "Certificate") formerly representing any of such Shares (other
than Excluded Shares) shall thereafter represent only the right
-4-
<PAGE>
to receive the Merger Consideration, cash in lieu of fractional shares pursuant
to Section 4.2(e), if any, and any distribution or dividend pursuant to Section
4.2(c).
(b) Cancellation of Excluded Shares. Each Excluded Share
issued and outstanding immediately prior to the Effective Time shall, by virtue
of the Merger and without any action on the part of the holder thereof, cease to
be outstanding, shall be canceled and retired without payment of any
consideration therefor and shall cease to exist.
(c) Merger Sub. As of and following the Effective Time, each
share of Common Stock, par value $.01 per share, of Merger Sub issued and
outstanding immediately prior to the Effective Time shall continue to remain
outstanding and shall constitute one share of common stock of the Surviving
Corporation.
4.2. Exchange of Certificates for Shares.
(a) Exchange Agent. As of the Effective Time, Parent shall
deposit, or shall cause to be deposited, with an exchange agent selected by
Parent and reasonably acceptable to the Company (the "Exchange Agent"), for the
benefit of the holders of Shares, certificates representing the shares of Parent
Common Stock and, after the Effective Time, if applicable, any cash, dividends
or other distributions with respect to the Parent Common Stock to be issued or
paid pursuant to Section 4.1(a)(ii) (including cash in lieu of fractional
shares) to be exchanged for Shares outstanding immediately prior to the
Effective Time upon due surrender of the Certificates (or affidavits of loss in
lieu thereof) pursuant to the provisions of this Article IV (such certificates
for shares of Parent Common Stock, together with the amount of any dividends or
other distributions payable with respect thereto and any cash in lieu of
fractional shares, being hereinafter referred to as the "Exchange Fund").
(b) Exchange Procedures. Promptly after the Effective Time,
the Surviving Corporation shall cause the Exchange Agent to mail to each holder
of record of Shares (other than holders of Excluded Shares) (i) a letter of
transmittal specifying that delivery shall be effected, and risk of loss and
title to the Certificates shall pass, only upon delivery of the Certificates (or
affidavits of loss in
-5-
<PAGE>
lieu thereof) to the Exchange Agent and (ii) instructions for use in effecting
the surrender of the Certificates in exchange for (A) certificates representing
shares of Parent Common Stock and (B) any unpaid dividends and other
distributions and cash in lieu of fractional shares. Subject to Section 4.2(g),
upon surrender of a Certificate for cancellation to the Exchange Agent together
with such letter of transmittal, duly executed, the holder of such Certificate
shall be entitled to receive in exchange therefor (x) a certificate representing
that number of whole shares of Parent Common Stock that such holder is entitled
to receive pursuant to this Article IV and (y) a check in the amount (after
giving effect to any required tax withholdings) of (A) any cash in lieu of
fractional shares as provided in Section 4.2(e) plus (B) any unpaid non-stock
dividends and any other dividends or other distributions that such holder has
the right to receive pursuant to the provisions of this Article IV, and the
Certificate so surrendered shall forthwith be canceled. No interest will be paid
or accrued on any amount payable upon due surrender of the Certificates. In the
event of a transfer of ownership of Shares that is not registered in the
transfer records of the Company, a certificate representing the proper number of
shares of Parent Common Stock, together with a check for any cash to be paid
upon due surrender of the Certificate and any other dividends or distributions
in respect thereof, may be issued and/or paid to such a transferee if the
Certificate formerly representing such Shares is presented to the Exchange
Agent, accompanied by all documents required to evidence and effect such
transfer and to evidence that any applicable stock transfer taxes have been
paid. If any certificate for shares of Parent Common Stock is to be issued in a
name other than that in which the Certificate surrendered in exchange therefor
is registered, it shall be a condition of such exchange that the Person (as
defined below) requesting such exchange shall pay any transfer or other taxes
required by reason of the issuance of certificates of shares of Parent Common
Stock in a name other than that of the registered holder of the Certificate
surrendered, or shall establish to the satisfaction of Parent or the Exchange
Agent that such tax has been paid or is not applicable.
For the purposes of this Agreement, the term "Person" shall
mean any individual, corporation (including not-for-profit), general or limited
partnership, limited liability company, joint venture, estate, trust,
-6-
<PAGE>
association, organization, Governmental Entity (as defined in Section 5.1(d)) or
other entity of any kind or nature.
(c) Distributions with Respect to Unexchanged Shares; Voting.
(i) All shares of Parent Common Stock to be issued pursuant to the Merger shall
be deemed issued and outstanding as of the Effective Date and whenever a
dividend or other distribution is declared by Parent in respect of the Parent
Common Stock, the record date for which is at or after the Effective Time, that
declaration shall include dividends or other distributions in respect of all
shares issuable pursuant to this Agreement. No dividends or other distributions
in respect of the Parent Common Stock shall be paid to any holder of any
unsurrendered Certificate until such Certificate is surrendered for exchange in
accordance with this Article IV. Subject to the effect of applicable laws,
reasonably promptly following surrender of any such Certificate, there shall be
issued and/or paid to the holder certificates representing whole shares of
Parent Common Stock issued in exchange therefor, without interest, (A) at the
time of such surrender, the dividends or other distributions with a record date
after the Effective Time theretofore payable with respect to such whole shares
of Parent Common Stock and not paid and (B) at the appropriate payment date, the
dividends or other distributions payable with respect to such whole shares of
Parent Common Stock with a record date after the Effective Time but with a
payment date subsequent to surrender.
(ii) Holders of unsurrendered Certificates shall be entitled
to vote after the Effective Time at any meeting of Parent stockholders the
number of whole shares of Parent Common Stock represented by such Certificates,
regardless of whether such holders have exchanged their Certificates.
(d) Transfers. After the Effective Time, there shall be no
transfers on the stock transfer books of the Company of the Shares that were
outstanding immediately prior to the Effective Time.
(e) Fractional Shares. Notwithstanding any other provision of
this Agreement, no fractional shares of Parent Common Stock will be issued and
any holder of Shares entitled to receive a fractional share of Parent Common
Stock but for this Section 4.2(e) shall be entitled to receive, as of the date
on which those holders entitled to receive fractional shares are determined, a
cash payment in
-7-
<PAGE>
lieu of such fractional share, without interest, which payment shall represent
such holder's proportionate interest in the net proceeds from the sale by the
Exchange Agent on behalf of such holder of the aggregate fractional shares of
Parent Common Stock that such holder otherwise would be entitled to receive. Any
such sale shall be made by the Exchange Agent on the date on which those holders
entitled to receive fractional shares are determined.
(f) Termination of Exchange Fund. Any portion of the Exchange
Fund (including the proceeds of any investments thereof and any Parent Common
Stock) that remains unclaimed by the stockholders of the Company for 60 days
after the Effective Time shall be paid to Parent. Any stockholders of the
Company who have not theretofore complied with this Article IV shall thereafter
look only to Parent for payment of their shares of Parent Common Stock and any
cash, dividends and other distributions in respect of the Parent Common Stock
payable and/or issuable pursuant to Section 4.1 and Section 4.2(c) upon due
surrender of their Certificates (or affidavits of loss in lieu thereof), in each
case, without any interest thereon. Notwithstanding the foregoing, none of
Parent, the Surviving Corporation, the Exchange Agent or any other Person shall
be liable to any former holder of Shares for any amount properly delivered to a
public official pursuant to applicable abandoned property, escheat or similar
laws.
(g) Lost, Stolen or Destroyed Certificates. In the event any
Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the Person claiming such Certificate to be lost,
stolen or destroyed and, if required by Parent, the posting by such Person of a
bond in an amount determined by Parent as indemnity against any claim that may
be made against it with respect to such Certificate, the Exchange Agent will
issue in exchange for such lost, stolen or destroyed Certificate the shares of
Parent Common Stock and any cash payable and any unpaid dividends or other
distributions in respect of Parent Common Stock pursuant to Section 4.2(c) upon
due surrender of and deliverable in respect of the Shares represented by such
Certificate pursuant to this Agreement.
4.3. Dissenters' Rights. In accordance with Section 262 of the
DGCL, no appraisal rights shall be available to holders of Shares in connection
with the Merger.
-8-
<PAGE>
4.4. Adjustments to Prevent Dilution. In the event that (i) on
or after the date hereof and prior to the Effective Time the Company changes the
number of Shares or securities convertible or exchangeable into or exercisable
for Shares (except as specifically contemplated by or permitted by this
Agreement or the Schedules hereto), or (ii) Parent changes the number of shares
of Parent Common Stock or securities convertible or exchangeable into or
exercisable for shares of Parent Common Stock issued and outstanding prior to
the Effective Time as a result of a reclassification, stock split (including a
reverse split) with a record date prior to the Effective Time, stock dividend or
distribution with a record date prior to the Effective Time, recapitalization,
merger, subdivision, issuer tender or exchange offer, or other similar
transaction, then, in either such case, the Merger Consideration shall be
equitably adjusted.
4.5. Treatment of Convertible Notes. The Convertible Notes and
Warrants (as each such term is defined in Section 5.1(b)) shall be treated as
set forth in Section 6.16.
ARTICLE V
Representations and Warranties
5.1. Representations and Warranties of the Company. The
Company hereby represents and warrants to Parent and Merger Sub as follows:
(a) Organization, Good Standing and Qualification. Each of
the Company and its Subsidiaries is a corporation duly organized, validly
existing and in good standing (where such concept is recognized) under the laws
of its respective jurisdiction of organization and has all requisite corporate
or similar power and authority to own and operate its properties and assets and
to carry on its business as presently conducted and is qualified to do business
and is in good standing as a foreign corporation in each jurisdiction (where
such concept is recognized) where the ownership or operation of its properties
or conduct of its business requires such qualification, except where the failure
of any of the Company's Subsidiaries to be so qualified or in such good
standing, when taken together with all other such failures, is not reasonably
likely to have a
-9-
<PAGE>
Company Material Adverse Effect (as defined below) or materially impair the
ability of the Company, the Surviving Corporation, Parent or any of their
respective affiliates, following consummation of the Merger, to conduct any
material business or operations in any jurisdiction where they are now being
conducted. The Company has made available to Parent a complete and correct copy
of the Company's and its Subsidiaries' certificates of incorporation and bylaws
(or documents of a similar scope for corporations organized in jurisdictions
outside the United States), each as amended to date. The Company's and its
Subsidiaries' certificates of incorporation and bylaws (or similar documents) so
delivered are in full force and effect. Schedule 5.1(a) contains a correct and
complete list of each jurisdiction under the laws of which the Company and each
of its Subsidiaries is organized.
As used in this Agreement, (i) "Subsidiary" means, with
respect to the Company, Parent or Merger Sub, as the case may be, any entity,
whether incorporated or unincorporated, of which at least a majority of the
securities or ownership interests having by their terms ordinary voting power to
elect a majority of the board of directors or other persons performing similar
functions is directly or indirectly owned or controlled by such party or by one
or more of its respective Subsidiaries or by such party and any one or more of
its respective Subsidiaries, (ii) "Company Material Adverse Effect" means any
change in or effect on the business of the Company and its Subsidiaries that is,
or is reasonably likely to be, materially adverse to the business, assets
(including intangible assets), liabilities (contingent or otherwise), prospects,
condition (financial or otherwise) of the Company and its Subsidiaries, taken as
a whole or the Projected Expenses; provided, however, that changes in or effects
on the financial condition of the Company and its Subsidiaries, taken as a
whole, that result solely from expenditures by the Company and its Subsidiaries
which do not exceed the Projected Expenses and expenses incurred in connection
with the transactions contemplated by this Agreement shall not, in and of
themselves, constitute a Company Material Adverse Effect, and changes in or
effects on the financial condition or results of operation of the Company and
its Subsidiaries, taken as a whole, that result solely from decreases in the
revenues of the Company and its Subsidiaries shall not, in and of themselves,
constitute a Company Material Adverse Effect, (iii) "Projected Expenses" means
the aggregate projected expenses for the periods up to
-10-
<PAGE>
and including the Closing Date set forth in the budget of the Company set forth
in Schedule 6.1(a) (the "Budget"), and (iv) "due investigation" means a
commercially reasonable investigation for a company engaged in a business
similar to that of the Company.
(b) Capital Structure. The authorized capital stock of the
Company consists of 30,000,000 Shares, of which only 16,951,307 Shares were
outstanding as of the close of business on June 14, 1999, and 20,000,000 shares
of Preferred Stock, par value $0.01 per share (the "Preferred Shares"), of which
none are outstanding. All of the outstanding Shares have been duly authorized
and are validly issued, fully paid and nonassessable. Other than Shares reserved
for issuance pursuant to the Stock Option Agreement, the Company has no Shares
or Preferred Shares subject to issuance, except (i) 300,000 Preferred Shares,
designated Series A Junior Participating Preferred Stock, subject to issuance
upon exercise of the Rights (the "Rights") issued pursuant to the Rights
Agreement, dated as of August 1, 1995 (the "Rights Agreement"), between the
Company and The First National Bank of Boston, as Rights Agent, (ii) 1,681,839
Shares subject to issuance upon conversion of the Company's 12% Senior
Convertible Notes due 2002 (the "12% Notes"), (iii) 1,261,385 Shares subject to
issuance upon conversion of 12% Senior Convertible Notes (the "Warrant Notes")
issuable upon exercise of outstanding warrants to purchase Warrant Notes (the
Warrants Notes, collectively with the 12% Notes, the "Convertible Notes"), (iv)
1,806,776 Shares reserved for issuance in connection with the payment of
interest on the Convertible Notes (it being agreed that any such issuance shall
constitute a breach of this Agreement), (v) 675,798 Shares reserved for issuance
pursuant to the warrants summarized in Schedule 5.1(b) (the "Warrants"), (vi)
3,187,244 shares reserved for issuance under the Company's 1992 Stock Option
Plan, as amended, of which options to acquire 2,601,393 shares are outstanding
as of June 14, 1999, (vii) 298,000 shares reserved for issuance under the
Company's 1994 Non-Employee Directors' Stock Option Plan, of which options to
acquire 165,000 shares are outstanding as of June 14, 1999, (viii) 270,000
shares reserved for issuance under the Company's Long-Term Objectives Stock
Option Plan for Senior Management, of which options to acquire 180,000 shares
are outstanding as of June 14, 1999, (xi) 206,422 shares reserved for issuance
under the Company's Employee Stock Purchase Plan as of June 14, 1999, and (x)
50,000 Shares subject to issuance pursuant to
-11-
<PAGE>
the Letter Agreement, dated as of July 21, 1998, by and between the Company and
Stephen Evans-Freke (the "Letter Agreement"). Schedule 5.1(b) sets forth a
correct and complete list of each outstanding option to purchase Shares under
the Stock Plans, as defined below (each a "Company Option"), as of June 14,
1999, including the holder, date of grant, exercise price and number of Shares
subject thereto. All issued and outstanding shares of capital stock or other
securities of each of the Company's Subsidiaries are duly authorized, validly
issued, fully paid and nonassessable and, except for directors' qualifying
shares, owned by a direct or indirect wholly owned Subsidiary of the Company,
free and clear of any lien, pledge, security interest, claim or other
encumbrance, other than immaterial liens which do not affect the Company's
right, title and interest in and to such shares or securities. Except as set
forth above or as disclosed in Schedule 5.1(b) or as specifically permitted by
this Agreement or the Schedules hereto, there are no shares of capital stock of
the Company authorized, issued or outstanding and except as set forth above and
as provided in the Stock Option Agreement, there are no preemptive rights nor
any outstanding subscriptions, options, warrants, rights, convertible securities
or other agreements or commitments of any character to which the Company or any
of its Subsidiaries is a party or may be bound relating to the issued or
unissued capital stock or other securities of the Company or any of its
Subsidiaries. Except for the Warrants and the Convertible Notes as described
above, the Company does not have outstanding any bonds, debentures, notes or
other obligations the holders of which have the right to vote (or convertible
into or exercisable for securities having the right to vote) with the
stockholders of the Company on any matter ("Voting Debt"). Except for the
Company's 1992 Stock Option Plan, 1994 Non-Employee Directors' Stock Option
Plan, Long-Term Objectives Stock Option Plan for Senior Management, Employee
Stock Purchase Plan and the Letter Agreement (such plans and agreements
collectively, the "Stock Plans"), at or after the Effective Time, neither the
Surviving Corporation nor Parent nor their respective affiliates will have any
obligation to issue, transfer or sell any shares or securities of the Surviving
Corporation, Parent or any of their respective affiliates pursuant to any
Compensation and Benefit Plan (as defined in Section 5.1(h)(i)). No Shares,
Preferred Shares or other securities of the Company, the Surviving Corporation,
Parent or any of their respective affiliates will be subject to issuance
pursuant to the Rights Agreement as a result of the
-12-
<PAGE>
Merger or the other transactions contemplated by this Agreement, the Stock
Option Agreement and the Voting Agreement and no Distribution Date or Shares
Acquisition Date (as such terms are defined in the Rights Agreement) shall have
occurred as a result of the Merger or the other transactions contemplated by
this Agreement, the Stock Option Agreement and the Voting Agreement.
(c) Corporate Authority; Approval and Fairness. (i) The
Company has all requisite corporate power and authority and has taken all
corporate action necessary in order to execute, deliver and perform its
obligations under this Agreement and the Stock Option Agreement and to
consummate, subject only to obtaining the adoption of this Agreement by a
majority of the shares outstanding as of the record date of the Company's
stockholders meeting (the "Company Requisite Vote"), the Merger. This Agreement
and the Stock Option Agreement are valid and binding agreements of the Company,
enforceable against the Company in accordance with their respective terms.
(ii) The board of directors of the Company (A) has unanimously
approved this Agreement and the Stock Option Agreement and the Merger and the
other transactions contemplated hereby and thereby and (B) has received the oral
opinion of its financial advisors, Lehman Brothers Inc., to the effect that the
consideration to be received by the holders of the Shares in the Merger is fair
to such holders from a financial point of view, which opinion will be confirmed
in writing promptly after the date hereof (and a copy of such written opinion
will be promptly delivered to Parent). It is agreed and understood that such
opinion is for the sole benefit of the Company's board of directors and may not
be relied on by Parent or Merger Sub.
(d) Governmental Filings; No Violations. (i) Other than any
filings and/or notices required (A) pursuant to Section 1.3, (B) under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR
Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and
the Securities Act of 1933, as amended (the "Securities Act"), (C) to comply
with state securities or "blue sky" laws, and (D) such filings or consents,
registrations, approvals, permits or authorizations as may be required under the
competition or antitrust laws of jurisdictions outside the United States, no
notices or other filings are required to be made with, nor are any consents,
-13-
<PAGE>
registrations, approvals, permits or authorizations required to be obtained by
the Company from, any governmental or regulatory authority, agency, commission,
body or other governmental entity ("Governmental Entity"), in connection with
the execution and delivery of this Agreement and the Stock Option Agreement by
the Company and the consummation by the Company of the Merger and the other
transactions contemplated hereby and thereby, except those that the failure to
make or obtain are not, individually or in the aggregate, reasonably likely to
have a Company Material Adverse Effect or prevent, materially delay or
materially impair the ability of the Company to consummate the transactions
contemplated by this Agreement and the Stock Option Agreement or materially
impair the ability of the Company, the Surviving Corporation, Parent or any of
their respective affiliates, following consummation of the Merger, to conduct
any material business or operations in any jurisdiction where they are now being
conducted.
(ii) Except as set forth in Schedule 5.1(d)(ii), the
execution, delivery and performance of this Agreement and the Stock Option
Agreement by the Company do not and will not, and the consummation by the
Company of the Merger and the other transactions contemplated hereby and thereby
will not, constitute or result in (A) a breach or violation of, or a default
under, the certificate or bylaws of the Company or the comparable governing
instruments of any of its Subsidiaries, (B) a breach or violation of, or a
default under, the acceleration of any obligations or the creation of a lien,
pledge, security interest or other encumbrance on the assets of the Company or
any of its Subsidiaries (with or without notice, lapse of time or both) pursuant
to, any agreement, lease, contract, note, mortgage, indenture or other
obligation ("Contracts") binding upon the Company or any of its Subsidiaries or
any Law (as defined in Section 5.1(i)) or governmental or non-governmental
permit or license to which the Company or any of its Subsidiaries is subject, or
(C) any change in the rights or obligations of any party under any of the
Contracts, except, in the case of clause (B) or (C) above, for any breach,
violation, default, acceleration, creation or change that, individually or in
the aggregate, is not reasonably likely to have a Company Material Adverse
Effect, prevent, materially delay or materially impair the ability of the
Company to consummate the transactions contemplated by this Agreement and the
Stock Option Agreement or materially impair the ability of the Company, the
Surviving Corporation, Parent or
-14-
<PAGE>
any of their respective affiliates, following consummation of the Merger, to
conduct any material business or operations in any jurisdiction where they are
now being conducted. Schedule 5.1(d)(ii) sets forth a correct and complete list
of all consents and waivers which are or may be required in connection with the
consummation of the transactions contemplated by this Agreement and the Stock
Option Agreement (whether or not subject to the exception set forth with respect
to clause (B) or (C) above) under Contracts to which the Company or any of its
Subsidiaries is a party, other than any consent or waiver (other than consents
or waivers pursuant to Contracts relating to indebtedness, securities or the
guarantee thereof) the failure to obtain which is not reasonably likely to
materially affect the business or operations of the Company and its
Subsidiaries.
(e) Company Reports; Financial Statements. The Company and, to
the extent applicable, each of its then or current Subsidiaries has made all
filings required to be made by it with the SEC since October 4, 1994
(collectively, including any such reports filed subsequent to the date hereof,
the "Company Reports"). The Company has delivered or made available to Parent
each registration statement, report, proxy statement or information statement
filed with the Securities and Exchange Commission (the "SEC") by it since
December 31, 1998 (the "Audit Date"), including, without limitation, (i) the
Company's Annual Report on Form 10-K for the year ended December 31, 1998, (ii)
the Company's Quarterly Report for the quarter ended March 31, 1999, as amended,
(iii) the Company's Proxy Statement filed on April 20, 1999, (iv) the Company's
Registration Statement on Form S-3 filed on April 23, 1999, and (v) the
Company's Current Report on Form 8-K filed on March 29, 1999, all in the form
(including exhibits, annexes and any amendments thereto) filed with the SEC.
Except as set forth in Schedule 5.1(e), as of their respective dates, the
Company Reports did not, and any Company Reports filed with the SEC subsequent
to the date hereof will not, contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements made therein, in light of the circumstances in which they were
made, not misleading. Each of the consolidated balance sheets included in or
incorporated by reference into the Company Reports (including the related notes
and schedules) presents fairly, or will present fairly, in all material
respects, the consolidated financial
-15-
<PAGE>
position of the Company and its Subsidiaries as of its date and each of the
consolidated statements of income and of changes in financial position included
in or incorporated by reference into the Company Reports (including any related
notes and schedules) presents fairly, or will present fairly, in all material
respects, the results of operations, retained earnings and changes in financial
position, as the case may be, of the Company and its Subsidiaries for the
periods set forth therein (except as otherwise noted therein and subject, in the
case of unaudited statements, to notes and normal year-end audit adjustments
that will not be material in amount or effect), in each case in accordance with
generally accepted accounting principles ("GAAP") consistently applied during
the periods involved, except, in the case of unaudited financial statements, as
permitted by SEC Form 10-Q, and except as may be noted therein. Other than the
Company Reports specifically recited in clauses (i) through (v) of the first
sentence of this Section 5.1(e), the Company has not, on or prior to the date
hereof, filed any other definitive reports or statements with the SEC since the
Audit Date.
(f) Absence of Certain Changes. Except as disclosed in the
Company Reports filed prior to the date hereof or in Schedule 5.1(f), since the
Audit Date the Company and its Subsidiaries have conducted their respective
businesses in all material respects only in, and have not engaged in any
material transaction other than according to, the ordinary and usual course of
such businesses and there has not been (i) any change in the financial
condition, properties, business or results of operations of the Company or any
of its Subsidiaries or any occurrence or combination of occurrences of which the
Company has knowledge that, individually or in the aggregate, has had or is
reasonably likely to have a Company Material Adverse Effect; (ii) any material
damage, destruction or other casualty loss with respect to any material asset or
property owned, leased or otherwise used by the Company or any of its
Subsidiaries, whether or not covered by insurance; (iii) any declaration,
setting aside or payment of any dividend or other distribution in respect of
the capital stock of the Company; or (iv) other than as set forth in Schedule
5.1(f), any change by the Company in accounting principles, practices or
methods. Schedule 5.1(f) contains a document setting forth the name, title,
salary and other compensation of each employee of the Company as of June 14,
1999. Since the date of such document, there has not been any increase in the
-16-
<PAGE>
compensation payable or that could become payable by the Company or any of its
Subsidiaries to officers or key employees of the Company or its Subsidiaries, or
any amendment of any of the Stock Plans or Compensation and Benefit Plans.
(g) Litigation and Liabilities. Except as disclosed in
Schedule 5.1(g) or as disclosed in the Company Reports filed prior to the date
hereof, and except for matters which are not, individually or in the aggregate,
reasonably likely to have a Company Material Adverse Effect or prevent or
materially delay or materially impair the ability of the Company to consummate
the transactions contemplated by this Agreement and the Stock Option Agreement,
there are no (i) civil, criminal, administrative or regulatory actions, suits,
claims, hearings, investigations or proceedings pending or, to the knowledge of
the Company after due investigation, overtly threatened against the Company or
any of its Subsidiaries or (ii) obligations or liabilities, whether or not
accrued, contingent or otherwise and whether or not required to be disclosed,
including those relating to matters involving any Environmental Law (as defined
in Section 5.1(k)), other than liabilities incurred in the ordinary course of
business by the Company and its Subsidiaries since the Audit Date.
(h) Employee Benefits.
(i) The Company Reports accurately describe in all material
respects all incentive, bonus, deferred compensation, pension, retirement,
profit-sharing, thrift, savings, employee stock ownership, stock bonus, stock
purchase, restricted stock, stock option and other stock based plans, all
employment or severance agreements, plans, policies or arrangements, other
employee benefit plans and any applicable "change of control" or similar
provisions in any plan, agreement, policy or arrangement which covers current or
former employees of the Company and its subsidiaries (the "Compensation and
Benefit Plans"). The Compensation and Benefit Plans and all other benefit plans,
agreements, policies or arrangements covering current or former employees or
directors of the Company and its Subsidiaries (the "Employees"), including, but
not limited to, "employee benefit plans" within the meaning of Section 3(3) of
the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), are
listed in Schedule 5.1(h)(i). True and complete copies of all Compensation and
-17-
<PAGE>
Benefit Plans and such other benefit plans, agreements, policies or
arrangements, including, but to limited to, any trust instruments and/or
insurance contracts, if any, forming a part of any such plans and agreements,
and all amendments thereto have been provided or made available to Parent.
(ii) All employee benefit plans, other than "multiemployer
plans" within the meaning of Sections 3(37) of ERISA, covering Employees and
maintained in the United States (the "Plans"), to the extent subject to ERISA,
are in substantial compliance with ERISA. Each Plan which is an "employee
pension benefit plan" within the meaning of Section 3(2) of ERISA ("Pension
Plan") and which is intended to be qualified under Section 401(a) of the
Internal Revenue Code of 1986, as amended (the "Code"), has received a favorable
determination letter from the Internal Revenue Service, and the Company is not
aware of any circumstances likely to result in revocation of any such favorable
determination letter. There is no material pending or, to the knowledge of the
Company after due investigation, threatened, litigation relating to the Plans.
Neither the Company nor any of its Subsidiaries has engaged in a transaction
with respect to any Plan that, assuming the taxable period of such transaction
expired as of the date hereof, could subject the Company or any of its
Subsidiaries to a tax or penalty imposed by either Section 4975 of the Code or
Section 502(i) of ERISA in an amount which would be material.
(iii) No liability under Subtitle C or D of Title IV of ERISA
has been or is expected to be incurred by the Company or any of its Subsidiaries
with respect to any ongoing, frozen or terminated "single-employer plan," within
the meaning of Section 4001(a)(15) of ERISA, currently or formerly maintained by
any of them, or the single-employer plan of any entity which is considered one
employer with the Company under Section 4001 of ERISA or Section 414 of the Code
(an "ERISA Affiliate"). The Company and its Subsidiaries have not incurred and
do not expect to incur any withdrawal liability with respect to a multiemployer
plan under Subtitle E of Title IV of ERISA (regardless of whether based on
contributions of an ERISA Affiliate). No notice of a "reportable event," within
the meaning of Section 4043 of ERISA for which the 30-day reporting requirement
has not been waived, has been required to be filed for any Pension
-18-
<PAGE>
Plan or by any ERISA Affiliate within the 12-month period ending on the date
hereof.
(iv) All contributions required to be made under the terms of
any Plan have been timely made or accrued on the Company's financial statements.
Neither any Pension Plan nor any single-employer plan of an ERISA Affiliate has
an "accumulated funding deficiency" (whether or not waived) within the meaning
of Section 412 of the Code or Section 302 of ERISA and no ERISA Affiliate has an
outstanding funding waiver. Neither the Company nor any of its Subsidiaries has
provided, or is required to provide, security to any Pension Plan or to any
single-employer plan of an ERISA Affiliate pursuant to Section 401(a)(29) of the
Code.
(v) Under each Pension Plan which is a single-employer plan,
as of the last day of the most recent plan year ended prior to the date hereof,
the actuarially determined present value of all "benefit liabilities," within
the meaning of Section 4001(a)(16) of ERISA (as determined on the basis of the
actuarial assumptions contained in the Pension Plan's most recent actuarial
valuation), did not exceed the then current value of the assets of such Pension
Plan, and there has been no material change in the financial condition of such
Pension Plan since the last day of the most recent plan year. The withdrawal
liability of the Company and its Subsidiaries under each Compensation and
Benefit Plan which is a multiemployer plan within the meaning of Section 3(37)
of ERISA to which the Company, its Subsidiaries or an ERISA Affiliate has
contributed during the preceding 12 months, determined as if a "complete
withdrawal," within the meaning of Section 4203 of ERISA, had occurred as of the
date hereof, does not exceed $100,000.
(vi) Neither the Company nor any of its Subsidiaries has any
obligations for retiree health and life benefits under any Plan, except as set
forth on Schedule 5.1(h)(vi). The Company or its Subsidiaries may amend or
terminate any such Plan at any time without incurring any liability thereunder.
(vii) Except as set forth on Schedule 5.1(h)(vii), the
consummation of the transactions contemplated by this Agreement will not (x)
entitle any Employees to severance pay, (y) accelerate the time of payment or
vesting or trigger any payment or funding
-19-
<PAGE>
(through a grantor trust or otherwise) of compensation or benefits under,
increase the amount payable or trigger any other material obligation pursuant
to, any of the Compensation and Benefit Plans or (z) result in payments under
any of the Plans which would not be deductible under Section 162(m) or Section
280G of the Code.
(viii) All Compensation and Benefit Plans maintained outside
of the United States comply in all material respects with applicable local law.
The Company and its Subsidiaries have no material unfunded liabilities with
respect to any such Compensation and Benefit Plan.
(i) Compliance. Except as set forth in Schedule 5.1(i),
neither the Company nor any of its Subsidiaries is in default or violation of,
(i) any law, ordinance, rule, regulation, order, judgment, decree, arbitration
award, license or permit of any Governmental Entity (collectively, "Laws")
applicable to the Company or any of its Subsidiaries or by which its or any of
their respective properties are bound, or (ii) any Contract to which the Company
or any of its Subsidiaries is a party or by which the Company or any of its
Subsidiaries or its or any of their respective properties are bound or affected,
except for any such defaults or violations that, individually or in the
aggregate, are not reasonably likely to have a Company Material Adverse Effect,
or prevent or materially delay the transactions contemplated by this Agreement
or materially impair the ability of the Company, the Surviving Corporation,
Parent or any of their respective affiliates, following consummation of the
Merger, to conduct any material business or operations in any jurisdiction where
they are now being conducted. To the knowledge of the Company after due
investigation, no material change is required in the Company's or any of its
Subsidiaries' processes, properties or procedures in order to comply in all
material respects with any Laws, and the Company has not received any notice or
overt communication of any material noncompliance with any such Laws that has
not been cured.
(j) Antitakeover Statutes. The board of directors of the
Company has taken all necessary action to approve the transactions contemplated
by this Agreement, the Stock Option Agreement and the Voting Agreement such that
the restrictions under Section 203 of the DGCL shall not apply to such
transactions. No "fair price," "moratorium," "control share acquisition" or
other similar antitakeover
-20-
<PAGE>
statute or regulation (each, an "Antitakeover Statute") is applicable to the
Company, the Shares, the Merger, this Agreement, the Stock Option Agreement, the
Voting Agreement or the other transactions contemplated by this Agreement, the
Stock Option Agreement or the Voting Agreement.
(k) Environmental Matters. Except as disclosed in the Company
Reports filed with the SEC prior to the date hereof or in Schedule 5.1(k), (i)
the Company and its Subsidiaries have complied in all material respects at all
relevant times with all applicable Environmental Laws; (ii) to the knowledge of
the Company, after due investigation, no property currently or formerly owned or
operated by the Company or any of its Subsidiaries (including soils,
groundwater, surface water, buildings or other structures) has been contaminated
with any Hazardous Substance; (iii) to the knowledge of the Company, after due
investigation, neither the Company nor any of its Subsidiaries is subject to any
liability for Hazardous Substance disposal or contamination on any third party
property; (iv) to the knowledge of the Company, after due investigation, neither
the Company nor any of its Subsidiaries is subject to liability for any release
or threat of release of any Hazardous Substance; (v) neither the Company nor any
of its Subsidiaries has received any notice, demand, letter, claim or request
for information indicating that it may be in violation of or subject to
liability under any Environmental Law; (vi) neither the Company nor any of its
Subsidiaries is subject to any order, decree, injunction or other arrangement
with any Governmental Entity or any indemnity or other agreement with any third
party relating to liability under any Environmental Law; (vii) to the knowledge
of the Company, after due investigation, none of the properties of the Company
or any of its Subsidiaries contain any underground storage tanks,
asbestos-containing material, lead products, or polychlorinated biphenyls;
(viii) to the knowledge of the Company, after due investigation, there are no
other circumstances or conditions involving the Company or any of its
Subsidiaries that could reasonably be expected to result in any claims,
liability, investigations, costs or restrictions on the ownership, use, or
transfer of any property in connection with any Environmental Law; and (ix) the
Company has delivered or made available to Parent copies of all environmental
reports, studies, assessments, sampling data and other environmental information
in its possession relating to the Company or any of its
-21-
<PAGE>
Subsidiaries or any of their current or former properties or operations.
"Environmental Law" means any federal, state or local law,
regulation, order, decree, permit, authorization, common law or agency
requirement relating to (A) the protection, investigation or restoration of the
environment, health, safety, or natural resources, (B) the handling, use,
presence, disposal, release or threatened release of any Hazardous Substance or
(C) noise, odor, indoor air, employee exposure, wetlands, pollution,
contamination or any injury or threat of injury to persons or property relating
to any Hazardous Substance.
"Hazardous Substance" means any substance that is (A) listed,
classified or regulated pursuant to any Environmental Law; (B) any petroleum
product or by-product, asbestos-containing material, lead-containing paint or
plumbing, polychlorinated biphenyls, radioactive materials or radon; or (C) any
other substance which may be the subject of regulatory action by any
Governmental Authority in connection with any Environmental Law.
(l) Accounting and Tax Matters. As of the date hereof, the
Company does not have any knowledge of any fact or circumstance that would
prevent the Company from being a "poolable entity" for purposes of Opinion 16 of
the Accounting Principles Board or prevent the Merger and the other transactions
contemplated by this Agreement from qualifying as a "reorganization" within the
meaning of Section 368(a) of the Code.
(m) Taxation. (a) The Company and each of its Subsidiaries,
and any consolidated, combined or unitary group for tax purposes of which the
Company or any of its Subsidiaries is or has been a member, has timely filed all
Tax Returns required to be filed by it in the manner provided by law. All such
Tax Returns are true, correct and complete in all material respects. The Company
and each of its Subsidiaries have timely paid all Taxes due or required to be
withheld from amounts owing to any employee, creditor or third party or have
provided adequate reserves in their financial statements for any Taxes that have
not been paid, whether or not shown as being due on any Tax Returns. Except as
has been disclosed to Parent in Schedule 5.1(m): (i) no material claim for
unpaid Taxes has become a lien or encumbrance of any kind against the property
of the Company
-22-
<PAGE>
or any of its Subsidiaries or is being asserted against the Company or any of
its Subsidiaries; (ii) no audit, examination, investigation or other proceeding
in respect of Taxes is pending, threatened or being conducted by a Tax
authority; (iii) no material issues have been raised by the relevant taxing
authority in connection with any examination of the Tax Returns filed by the
Company and its Subsidiaries; (iv) no extension or waiver of the statute of
limitations on the assessment of any Taxes has been granted by the Company or
any of its Subsidiaries and is currently in effect; (v) neither the Company nor
any of its Subsidiaries is a party to, is bound by, or has any obligation under,
or potential liability with regards to, any Tax sharing agreement, Tax
indemnification agreement or similar contract or arrangement; (vi) no power of
attorney has been granted by or with respect to the Company or any of its
Subsidiaries with respect to any matter relating to Taxes; (vii) neither the
Company nor any of its Subsidiaries is a party to any agreement, plan, contract
or arrangement that would result, separately or in the aggregate, in the payment
of any "excess parachute payments" within the meaning of Section 280G of the
Code; (viii) neither the Company nor any of its Subsidiaries has any deferred
intercompany gain or loss arising as a result of a deferred intercompany
transaction within the meaning of Treasury Regulation Section 1.1502-13 (or
similar provision under state, local or foreign law) or any excess loss accounts
within the meaning of Treasury Regulation Section 1.1502-19; (ix) the Company is
not and has not been a United States real property holding corporation (as
defined in Section 897(c)(2) of the Code) during the applicable period specified
in Section 897(c)(1)(ii) of the Code; (x) neither the Company nor any of its
Subsidiaries has been the subject to a Tax ruling that has continuing effect;
and (xi) neither the Company nor any of its Subsidiaries has agreed to include,
or is required to include, in income any adjustment under either Section 481(a)
or 482 of the Code (or an analogous provision of state, local or foreign law) by
reason of a change in accounting method or otherwise.
(b) Except as disclosed in Schedule 5.1(m), as of the date of
this Agreement, to the knowledge of the Company after due investigation, there
are no facts or circumstances that have materially adversely affected or are
reasonably likely to materially adversely affect the ability of the Company or
its Subsidiaries to obtain the cantonal and Swiss federal tax benefits described
in the September
-23-
<PAGE>
1998 ruling of the Canton of Schaffhausen, the corresponding Business
Development Agreement, and the March 1999 ruling of the Swiss Federal Office for
Economy and Labor, respectively.
"Taxes" means any taxes of any kind, including but not limited
to those on or measured by or referred to as income, gross receipts, capital,
sales, use, ad valorem, franchise, profits, license, withholding, employment,
payroll, premium, value added, property or windfall profits taxes, environmental
transfer taxes, customs, duties or similar fees, assessments or charges of any
kind whatsoever, together with any interest and any penalties, additions to tax
or additional amounts imposed by any governmental authority, domestic or
foreign.
"Tax Return" means any return, report or statement required to
be filed with any governmental authority with respect to Taxes.
(n) Certain Regulatory Matters. (i) Schedule 5.1(n) sets forth
a complete and accurate list for the last five years, of (A) all Warning Letters
(as defined below), Section 305 notices and similar letters or notices issued by
the Food and Drug Administration (the "FDA") or any other governmental entity,
domestic or foreign, that is concerned with the quality, identity, strength,
purity, safety, efficacy or manufacturing of the pharmaceutical compounds or
products tested or sold by the Company or its Subsidiaries (any such
governmental entity, a "Pharmaceutical Regulatory Agency") to the Company or any
of its Subsidiaries; (B) all United States Pharmacopoeia product problem
reporting program complaints or reports, MedWatch form FDA-3500A, FDA-1639 or
Form CIMOS I filed by the Company or any of its Subsidiaries, which complaints
or reports pertain to any incident involving death or serious injury, and for
which incident there has been (I) a notice or follow-up inquiry to the Company
or any of its Subsidiaries by the FDA, (II) a litigation or arbitration claim or
cause of action commenced, or (III) a notice to any insurance carrier of the
Company or any of its Subsidiaries tendering the defense or giving any notice of
a possible or actual claim against the Company or such subsidiary; (C) all
product recalls conducted by or issued to the Company or any of its Subsidiaries
and any requests from the FDA or any other Pharmaceutical Regulatory Agency
requesting the Company or any of its Subsidiaries to cease to investigate,
-24-
<PAGE>
test or market any compound or product; (D) any civil penalty actions begun by
the FDA or any other Pharmaceutical Regulatory Agency against the Company or any
of its Subsidiaries and all consent decrees and all documents relating to the
negotiation of and compliance with such consent decree issued with respect to
the Company or any of its Subsidiaries; and (E) any other written communications
between the Company or any of its Subsidiaries, on the one hand, and the FDA or
any other Pharmaceutical Regulatory Agency on the other hand that describe
matters that could have a material adverse effect on the projected sales or
revenues attributable to any compound, product or product line of the Company or
its Subsidiaries or discuss material issues concerning the quality, identity,
strength, purity, safety or efficacy of any such compound, product or product
line. The Company has made available to Parent copies of all documents referred
to in Schedule 5.1(n), as well as copies of all complaints and other information
required to be maintained by the Company pursuant to the United States Federal
Food, Drug and Cosmetic Act and Comprehensive Drug Abuse Prevention and Control
Act of 1970 and the corresponding laws of jurisdictions other than the United
States. For purposes of this subparagraph (i), "Warning Letter" means a letter
characterized by the FDA or any other Pharmaceutical Regulatory Agency as a
warning letter, a notice of adverse finding or a similar letter or report in
which FDA or any other Pharmaceutical Regulatory Agency expresses the opinion
that violations of law have occurred.
(ii) With such exceptions as are not material with respect to
(x) any of compounds SU101, SU5271, SU5416 or SU6668 or (y) the other compounds
and products of the Company and its Subsidiaries, taken as a whole and except as
set forth in Schedule 5.1(n), (A) the Company (or, if applicable, one of its
Subsidiaries) has obtained all consents, approvals, certifications,
authorizations and permits of, and has made all filings with, or notifications
to, all Pharmaceutical Regulatory Agencies pursuant to applicable requirements
of all FDA regulations and consent decrees, and all applicable state and foreign
laws, and regulations applicable to the Company or any of its Subsidiaries; (B)
all representations made by the Company or any of its Subsidiaries in connection
with any such consents, approvals, certifications, authorizations, permits,
filings and notifications were true and correct in all material respects at the
time such representations and warranties were made, and the Company's compounds
and
-25-
<PAGE>
products, and the compounds and products of its Subsidiaries, substantially
comply with, and perform in accordance with the specifications described in,
such representations; (C) the Company and its Subsidiaries and their respective
products and all of the facilities and entities which manufacture such compounds
and products, are in substantial compliance with all applicable FDA rules,
regulations and consent decrees, and all applicable state and foreign laws,
rules and regulations (including Good Manufacturing Practices) relating to
pharmaceutical manufacturers and distributors or otherwise applicable to the
Company's or its Subsidiaries' business; and (D) the Company has no reason to
believe that any of the consents, approvals, authorizations, registrations,
certifications, permits, filings or notifications that it or any of its
Subsidiaries has received or made to operate their respective businesses have
been or are being revoked or challenged.
(o) Intellectual Property.
(i) Set forth in Schedule 5.1(o)(i) is a complete list of each
of the following items (1) all patents and applications therefor, registrations
of trademarks (including service marks) and applications therefor, and
registrations of copyrights and applications therefor that are owned by the
Company or any of its Subsidiaries or licensed to the Company or any of its
Subsidiaries (collectively, the "Company Owned IP"), (2) all licenses,
agreements and contracts relating to the Company Intellectual Property (as
defined in Section 5.1(o)(ii) of this Agreement) pursuant to which the Company
or any of its Subsidiaries are entitled to use any Company Intellectual Property
owned by any third party (the "Third Party Licenses") and (3) all agreements
under which the Company or any of its Subsidiaries has granted any third party
the right to use any Company Intellectual Property, including the unexpired
material transfer agreements.
(ii) Except to the extent identified in Schedule 5.1 (o)(ii)
and except for any failures of this representation and warranty to be true and
accurate that arise from instances involving the infringement by the Company or
its Subsidiaries on the intellectual property rights of others or the
infringement by others on intellectual property rights of the Company or its
Subsidiaries of which, in either such case, the Company does
-26-
<PAGE>
not have any knowledge after due investigation, the Company, or its Subsidiaries
where expressly indicated, is the owner of, or is licensed to use, or otherwise
possesses legally enforceable rights in, all intellectual property, including,
without limitation, all patents and patent applications, supplementary
protection certificates and patent extensions, trademarks and trademark
applications, service mark and service mark registrations, logos, commercial
symbols, business name registrations, trade names, copyrights and copyright
registrations, computer software, mask works and mask work registration
applications, industrial designs and applications for registration of such
industrial designs, including, without limitation, any and all applications for
renewal, extensions, reexaminations and reissues of any of the foregoing
intellectual property rights where applicable, inventions, biological materials,
trade secrets, formulae, know-how, technical information, research data,
research raw data, laboratory notebooks, procedures, designs, proprietary
technology and information held or used in the business of the Company and its
Subsidiaries (hereinafter the "Company Intellectual Property").
(iii) Except to the extent identified in Schedule 5.1(o)(iii),
the Company and its Subsidiaries are the sole legal and beneficial owners of all
the Company Intellectual Property (except for the Company Intellectual Property
that is the subject of any Third Party Licenses) and all the Company
Intellectual Property is valid and subsisting.
(iv) The Company has not entered into any agreements, licenses
or created any mortgages, liens, security interests, leases, pledges,
encumbrances, equities, claims, charges, options, restrictions, rights of first
refusal, title retention agreements or other exceptions to title which affect
the Company Intellectual Property or restrict the use by the Company or any of
its Subsidiaries of the Company Intellectual Property in any way, except as
provided in agreements and instruments disclosed in Schedule 5.1(o)(ii) and
furnished to Parent prior to the date of this Agreement.
(v) Except as listed in Schedule 5.1(o)(v), to the knowledge
of the Company after due investigation, the Company and its Subsidiaries are in
compliance in all material respects with the Third Party Licenses that are
material to the conduct of the business of the Company.
-27-
<PAGE>
(vi) The Company and its Subsidiaries are not, and will not be
as a result of the execution, delivery or performance of this Agreement, the
Stock Option Agreement or the Voting Agreement or the consummation of the Merger
or the other transactions contemplated hereby or thereby in breach, violation or
default of any Third Party Licenses that are material to the conduct of the
business of the Company. Except as indicated in Schedule 5.1(o)(vi), the rights
of the Company or any of its Subsidiaries to the Company Intellectual Property
will not be affected by the execution, delivery or performance of this
Agreement, the Stock Option Agreement or the Voting Agreement or the
consummation of the Merger or the other transactions contemplated hereby or
thereby.
(vii) The Company and its Subsidiaries have the right to
license to third parties the use of the Company Owned IP.
(viii) Except as listed in Schedule 5.1(o)(viii), all
registrations and filings relating to the Company Owned IP are in good standing.
All maintenance and renewal fees necessary to preserve the rights of the Company
in respect of the Company Owned IP have been made. Except as indicated in
Schedule 5.1(o)(viii), the registrations and filings relating to the Company
Owned IP are proceeding and there are no material facts of which the Company has
knowledge after due investigation which could significantly undermine those
registrations or filings or reduce to a significant extent the scope of
protection of any patents arising from such applications.
(ix) The manufacturing, marketing, distribution, sale and use
of SU101, SU5271, SU5416 and SU6668 by the Company or its Subsidiaries,
licensees or sublicensees in the countries where the Company has conducted or
proposes to conduct such activities, to the knowledge of the Company after due
investigation, does not and would not infringe the patents, patent applications,
trademarks, trademark applications, service marks, service mark applications,
copyrights, copyright applications, and proprietary trade names, publication
rights, computer programs (including source code and object code), inventions,
know-how, trade secrets, technology, processes, confidential information and all
other intellectual property rights throughout the world (collectively,
"Intellectual Property Rights") of any third party.
-28-
<PAGE>
(x) Except for the matters set forth in Schedule 5.1(o)(x),
there are no allegations, claims or proceedings instituted or pending which
challenge the rights possessed by the Company or its Subsidiaries to use the
Company Intellectual Property or the validity or effectiveness of the Company
Intellectual Property, including without limitation any interferences,
oppositions, cancellations or other contested proceedings.
(xi) There are no outstanding claims or proceedings instituted
or pending by any third party challenging the ownership, priority, scope or
validity or effectiveness of any Company Intellectual Property.
(xii) To the knowledge of the Company after due investigation,
there are no Intellectual Property Rights of any third party that have been or
would be infringed by the identification, manufacture, marketing, distribution
and sale and use of any products (except products SU101, SU5271, SU5416 and
SU6668, which are addressed by subparagraph (ix) above) that have been
identified for development by the Company.
(xiii) To the knowledge of the Company after due
investigation, there are no Intellectual Property Rights of any third party that
would be infringed by the continued practice of any technologies previously used
or presently in use by the Company.
(xiv) To the knowledge of the Company after due investigation,
except for the matters set forth in Schedule 5.1(o)(xiv), there is no
unauthorized use, infringement or misappropriation of the Company Intellectual
Property by any third party, including any employee or former employee of the
Company or any of its Subsidiaries.
(xv) Except for the matters set forth in Schedule 5.1(o)(xv),
the Company and its Subsidiaries have not granted any licenses, immunities,
options or other rights to the Company Intellectual Property which could provide
a third party with a defense to patent infringement proceedings, whether
domestic or foreign.
(xvi) Commercially reasonable measures have been taken to
maintain the confidentiality of the inventions, trade secrets, formulae,
know-how, technical information, research data, research raw data, laboratory
notebooks,
-29-
<PAGE>
procedures, designs, proprietary technology and information of the Company and
its Subsidiaries, and all other information the value of which to the Company or
any of its Subsidiaries is contingent upon maintenance of the confidentiality
thereof. Without limiting the generality of the foregoing, (1) each employee of
the Company and each consultant to the Company who has had access to proprietary
information with respect to the Company has entered into an agreement suitable
to vest ownership rights to any inventions, creations, developments, and works
in the Company and has entered into an agreement for maintaining the
confidential information of the Company and (2) each officer and director of the
Company has entered into an agreement to maintain the confidential information
of the Company, except for those individuals listed in Schedule 5.1(o)(xvi)
whose involvement in the business of the Company is described with specificity
therein.
(p) Product Registration Files. The product registration files
and dossiers of the Company and its Subsidiaries have been maintained in
accordance with reasonable industry standards. The Company and each of its
Subsidiaries has in its possession copies of all the material documentation
filed in connection with filings made by the Company or any of its Subsidiaries
for regulatory approval or registration of the compounds and products of the
Company or any of its Subsidiaries, as the case may be. To the knowledge of the
Company after due investigation, the filings made by the Company and its
Subsidiaries for regulatory approval or registration of the products of the
Company or any of its Subsidiaries did not contain any untrue statement of a
material fact or omit to state any material fact necessary to make the
statements therein not misleading.
(q) Year 2000 Compliance. Schedule 5.1(q) contains the
Company's Year 2000 plan, which indicates the actions to be taken pursuant to
such plan that have been completed as of the date of this Agreement and the
actions to be taken pursuant to such plan that have not been completed as of the
date of this Agreement and the aggregate expense expected to be incurred by the
Company in connection with the actions to be taken pursuant to such plan that
have not been completed as of the date of this Agreement.
(r) Labor Matters. Neither the Company nor any of its
Subsidiaries is a party to or otherwise bound by any
-30-
<PAGE>
collective bargaining agreement, contract or other agreement or understanding
with a labor union or labor organization, nor is the Company or any of its
Subsidiaries the subject of any material proceeding asserting that the Company
or any of its Subsidiaries has committed an unfair labor practice or is seeking
to compel it to bargain with any labor union or labor organization nor is there
pending or, to the knowledge of the Company after due investigation, threatened,
any labor strike, dispute, walkout, work stoppage, slow-down or lockout
involving the Company or any of its Subsidiaries.
(s) Rights Agreement. The Company has amended the Rights
Agreement to provide that neither Parent nor Merger Sub nor any of their
respective affiliates shall be deemed to be an Acquiring Person (as such term is
defined in the Rights Agreement), that neither a Distribution Date nor a Shares
Acquisition Date (as each such term is defined in the Rights Agreement) shall be
deemed to occur, and the Rights will not separate from the Shares, as a result
of the execution, delivery or performance of this Agreement, the Stock Option
Agreement or the Voting Agreement or the consummation of the Merger or the other
transactions contemplated hereby or thereby, and that none of the Company,
Parent, Merger Sub, nor the Surviving Corporation, nor any of their respective
affiliates, shall have any obligations under the Rights Agreement to any holder
(or former holder) of Rights as of and following the Effective Time.
(t) Brokers and Finders. Except as disclosed in Schedule
5.1(t), neither the Company nor any of its Subsidiaries, officers, directors or
employees has employed any broker or finder or incurred any liability for any
brokerage fees, commissions or finders' fees in connection with the Merger or
the other transactions contemplated by this Agreement, the Stock Option
Agreement or the Voting Agreement, except that the Company has employed Lehman
Brothers Inc. as its financial advisor, the arrangements with which have been
disclosed to Parent prior to the date hereof.
(u) Supply Arrangements. As of the date of this Agreement, to
the Company's knowledge after due investigation, there are no facts or
circumstances that have materially adversely affected or are reasonably likely
to materially adversely affect the continued supply (either for clinical
purposes or in bulk) of the active ingredients of
-31-
<PAGE>
the compounds of the Company and its Subsidiaries currently used in clinical
trials.
(v) Investigational Compounds. As of the date of this
Agreement, to the Company's knowledge after due investigation, there are no
facts or circumstances that have materially adversely affected or that
management of the Company has determined are reasonably likely to materially
adversely affect the commercialization of compound SU5416 or compound SU6668,
other than factors that are generally applicable to the development and
commercialization of pharmaceutical compounds that are not specific to the
Company or such compounds.
5.2. Representations and Warranties of Parent and Merger Sub.
Parent and Merger Sub each hereby represent and warrant to the Company as
follows:
(a) Capitalization of Merger Sub. The authorized capital
stock of Merger Sub consists of one thousand (1,000) shares of Common Stock, par
value $.01 per share, all of which are validly issued and outstanding. All of
the issued and outstanding capital stock of Merger Sub is, and at the Effective
Time will be, owned by Parent, and there are (i) no other shares of capital
stock or other voting securities of Merger Sub, (ii) no securities of Merger Sub
convertible into or exchangeable for shares of capital stock or voting
securities of Merger Sub and (iii) no options or other rights to acquire from
Merger Sub, and no obligations of Merger Sub to issue, any capital stock, voting
securities or securities convertible into or exchangeable for capital stock or
voting securities of Merger Sub. Merger Sub has not conducted any business prior
to the date hereof and has no, and prior to the Effective Time will have no,
assets, liabilities or obligations of any nature other than those incident to
its formation and pursuant to this Agreement and the Merger and the other
transactions contemplated by this Agreement.
(b) Organization, Good Standing and Qualification. Each of
Parent and its Subsidiaries is a corporation duly organized, validly existing
and in good standing (where such concept is recognized) under the laws of its
respective jurisdiction of organization and has all requisite corporate or
similar power and authority to own and operate its properties and assets and to
carry on its business as presently conducted and is qualified to do business and
is
-32-
<PAGE>
in good standing as a foreign corporation in each jurisdiction (where such
concept is recognized) where the ownership or operation of its properties or
conduct of its business requires such qualification, except where the failure to
be so qualified or in such good standing, when taken together with all other
such failures, is not reasonably likely to have a Parent Material Adverse Effect
(as defined below). Parent has made available to the Company a complete and
correct copy of Parent's certificate of incorporation and bylaws, as amended to
the date hereof. Parent's certificate of incorporation and bylaws so delivered
are in full force and effect.
As used in this Agreement, (i) "Parent Material Adverse
Effect" means any change in or effect on the business of Parent and its
Subsidiaries that is, or is reasonably likely to be, materially adverse to the
business, assets (including intangible assets), liabilities (contingent or
otherwise), prospects, condition (financial or otherwise) or results of
operations of Parent and its Subsidiaries taken as a whole, and (ii) a
"Significant Subsidiary" of the Company means with respect to the Company or
Parent, as the case may be, a direct or indirect Subsidiary of such party which
is a significant subsidiary within the meaning of Rule 1.02(w) of Regulation S-X
promulgated pursuant to the Exchange Act.
(c) Capital Structure. The authorized capital stock of Parent
consists of 1,500,000,000 shares of Parent Common Stock, of which only
508,718,107 shares were outstanding as of the close of business on June 14,
1999, and 100,000,000 shares of Preferred Stock, par value $.01 per share (the
"Parent Preferred Stock"), of which only 6,795 shares, designated the Series A
convertible Perpetual Preferred Stock (the "Series A Preferred Stock"), were
outstanding as of the close of business on June 14, 1999. All of the outstanding
shares of Parent Common Stock and Series A Preferred Stock have been duly
authorized and are validly issued, fully paid and nonassessable. Parent has no
Parent Common Stock or Parent Preferred Stock, designated Participating
Preferred Stock, subject to issuance or subject to issuance, except that as of
the close of business on June 14, 1999, there were 24,818,686 shares of Parent
Common Stock reserved for issuance pursuant to Parent's Long Term Incentive Plan
(the "Parent Stock Plan"), 5,087,181 shares of Parent Preferred Stock,
designated Participating Preferred Stock, subject to issuance pursuant to the
-33-
<PAGE>
Stockholder Protection Rights Agreement, dated as of March 4, 1997, between the
Parent and Harris Trust & Savings Bank, as Rights Agent, and 9,852,750 shares of
Parent Common Stock subject to issuance upon conversion of shares of Series A
Preferred Stock. Each of the outstanding shares of capital stock of each of
Parent's Significant Subsidiaries is duly authorized, validly issued, fully paid
and nonassessable and, except for directors' qualifying shares, owned by a
direct or indirect wholly owned subsidiary of Parent, free and clear of any
lien, pledge, security interest, claim or other encumbrance. Except as set forth
above, there are no shares of capital stock of Parent authorized, issued or
outstanding and except as set forth above, there are no preemptive rights nor
any outstanding subscriptions, options, warrants, rights, convertible securities
or other agreements or commitments of any character relating to the issued or
unissued capital stock or other securities of Parent. Parent does not have
outstanding any bonds, debentures, notes or other obligations the holders of
which have the right to vote (or convertible into or exercisable for securities
having the right to vote) with the stockholders of Parent on any matter.
(d) Corporate Authority.
(i) No vote of holders of capital stock of Parent is necessary
to approve this Agreement and the Merger and the other transactions contemplated
hereby. Each of Parent and Merger Sub has all requisite corporate power and
authority and each has taken all corporate action necessary in order to execute,
deliver and perform its obligations under this Agreement and to consummate the
Merger. Parent has all requisite power and authority and has taken all corporate
action necessary in order to execute, deliver and perform its obligations under
the Stock Option Agreement. This Agreement is a valid and binding agreement of
Parent and Merger Sub, enforceable against each of Parent and Merger Sub in
accordance with its terms. The Stock Option Agreement are valid and binding
agreements of Parent enforceable against Parent in accordance with their
respective terms.
(ii) Prior to the Effective Time, Parent will have taken all
necessary action to permit it to issue the number of shares of Parent Common
Stock required to be issued pursuant to Article IV. The Parent Common Stock,
-34-
<PAGE>
when issued, will be validly issued, fully paid and nonassessable, and no
stockholder of Parent will have any preemptive right of subscription or purchase
in respect thereof. The Parent Common Stock, when issued, will be registered
under the Securities Act and Exchange Act and registered or exempt from
registration under any applicable state securities or "blue sky" laws.
(e) Governmental Filings; No Violations. (i) Other than any
filings and/or notices required (A) pursuant to Section 1.3, (B) under the HSR
Act, the Securities Act and the Exchange Act, (C) to comply with state
securities or "blue sky" laws, (D) required to be made with the NYSE and the
Stockholm Stock Exchange, and (E) such filings or consents, registrations,
approvals, permits or authorizations as may be required under the laws of the
competition or antitrust laws of jurisdictions outside the United States, no
notices or other filings are required to be made by Parent or Merger Sub with,
nor are any consents, registrations, approvals, permits or authorizations
required to be obtained by Parent or Merger Sub from, any Governmental Entity,
in connection with the execution and delivery of this Agreement by Parent and
Merger Sub or the execution and delivery of the Stock Option Agreement by Parent
or the consummation by Parent and Merger Sub of the Merger and the other
transactions contemplated hereby and by the Stock Option Agreement, except those
that the failure to make or obtain are not, individually or in the aggregate,
reasonably likely to have a Parent Material Adverse Effect or prevent,
materially delay or materially impair the ability of Parent or Merger Sub to
consummate the transactions contemplated by this Agreement and the Stock Option
Agreement.
(ii) The execution, delivery and performance of this Agreement
and the Stock Option Agreement by Parent, by Parent and Merger Sub, as the case
may be, do not and will not, and the consummation by Parent and Merger Sub of
the Merger and the other transactions contemplated hereby and by the Stock
Option Agreement, will not, constitute or result in (A) a breach or violation
of, or a default under, the certificate or bylaws of Parent and Merger Sub or
the comparable governing instruments of any of its Subsidiaries, (B) a breach or
violation of, or a default under, the acceleration of or the creation of a lien,
pledge, security interest or other encumbrance on the assets of Parent or any of
its Subsidiaries (with or without notice, lapse of time
-35-
<PAGE>
or both) pursuant to, any Contracts binding upon Parent or any of its
Subsidiaries or any Law or governmental or non-governmental permit or license to
which Parent or any of its Subsidiaries is subject, or (C) any change in the
rights or obligations of any party under any of the Contracts, except, in the
case of clause (B) or (C) above, for breach, violation, default, acceleration,
creation or change that, individually or in the aggregate, is not reasonably
likely to have a Parent Material Adverse Effect or prevent, materially delay or
materially impair the ability of Parent or Merger Sub to consummate the
transactions contemplated by this Agreement.
(f) Parent Reports; Financial Statements. Parent and, to the
extent applicable, each of its then or current Subsidiaries, has made all
filings required to be made by it with the SEC since December 31, 1993
(collectively, including any such reports filed subsequent to the date hereof,
the "Parent Reports") and Parent has delivered or made available to the Company
each registration statement, report, proxy statement or information statement
filed with the SEC by it since December 31, 1998 (the "Parent Audit Date") in
the form (including exhibits and any amendments thereto) filed with the SEC. As
of their respective dates, the Parent Reports did not, and any Parent Reports
filed with the SEC subsequent to the date hereof will not, contain any untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements made therein, in light of the
circumstances in which they were made, not misleading. Each of the consolidated
balance sheets included in or incorporated by reference into the Parent Reports
(including the related notes and schedules) presents fairly, or will present
fairly, in all material respects, the consolidated financial position of Parent
and its Subsidiaries as of its date and each of the consolidated statements of
income and of changes in financial position included in or incorporated by
reference into the Parent Reports (including any related notes and schedules)
presents fairly, or will present fairly, the results of operations, retained
earnings and changes in financial position, as the case may be, of Parent and
its Subsidiaries for the periods set forth therein (except as noted therein and
subject, in the case of unaudited statements, to notes and normal year-end audit
adjustments that will not be material in amount or effect), in each case in
accordance with GAAP consistently applied during the periods involved, except,
in the case of
-36-
<PAGE>
unaudited statements, as permitted by SEC Form 10-Q and except as may be noted
therein.
(g) Absence of Certain Changes. Except as disclosed in the
Parent Reports filed prior to the date hereof, since the Parent Audit Date
Parent and its Subsidiaries have conducted their respective businesses in all
material respects only in, and have not engaged in any material transaction
other than according to, the ordinary and usual course of such businesses and
there has not been (i) any change in the financial condition, properties,
business or results of operations of Parent and its Subsidiaries, or any
occurrence or combination of occurrences of which Parent has knowledge that,
individually or in the aggregate, has had or is reasonably likely to have a
Parent Material Adverse Effect; (ii) any material damage, destruction or other
casualty loss with respect to any material asset or property owned, leased or
otherwise used by Parent or any of its Subsidiaries, whether or not covered by
insurance; (iii) any declaration, setting aside or payment of any dividend or
other distribution in respect of the capital stock of Parent, except for
regularly quarterly dividends declared and paid on shares of Parent Common Stock
and Series A Preferred Stock; or (iv) any change by Parent in accounting
principles, practices or methods.
(h) Litigation and Liabilities. Except as disclosed in the
Parent Reports filed prior to the date hereof, and except for matters which are
not, individually or in the aggregate, reasonably likely to have a Parent
Material Adverse Effect or prevent or materially delay or materially impair the
ability of Parent or Merger Sub to consummate the transactions contemplated by
this Agreement and the Stock Option Agreement, there are no (i) civil, criminal,
administrative or regulatory actions, suits, claims, hearings, investigations or
proceedings pending or, to the knowledge of Parent after due investigation,
overtly threatened against Parent or any of its Subsidiaries or (ii) obligations
or liabilities, whether or not accrued, contingent or otherwise and whether or
not required to be disclosed, including those relating to matters involving any
Environmental Law, other than liabilities incurred in the ordinary course of
business by Parent and its Subsidiaries since the Audit Date.
(i) Compliance. Neither Parent nor any of its Subsidiaries is
in default or violation of, (i) any Law
-37-
<PAGE>
applicable to Parent or any of its Subsidiaries or by which its or any of their
respective properties are bound, or (ii) any Contract to which Parent or any of
its Subsidiaries is a party or by which Parent or any of its Subsidiaries or its
or any of their respective properties are bound or affected, except for any such
defaults or violations that, individually or in the aggregate, are not
reasonably likely to have a Parent Material Adverse Effect or prevent or
materially delay the transactions contemplated by this Agreement.
(j) Accounting and Tax Matters. As of the date hereof, Parent
does not have any knowledge of any fact or circumstance relating to the Company
or its affiliates that would prevent Parent from accounting for the business
combination to be effected by the Merger as a "pooling of interests" or prevent
the Merger and the other transactions contemplated by this Agreement from
qualifying as a "reorganization" within the meaning of Section 368(a) of the
Code.
(k) Brokers and Finders. Neither Parent nor any of its
Subsidiaries, officers, directors or employees has employed any broker or finder
or incurred any liability for any brokerage fees, commissions or finders' fees
in connection with the Merger or the other transactions contemplated by this
Agreement, the Stock Option Agreement or the Voting Agreement, except that
Parent has employed Goldman, Sachs & Co. as its financial advisor.
ARTICLE VI
Covenants
6.1. Company Interim Operations. Except as set forth in the
document entitled "Schedule 6.1" furnished to the Company by Parent prior to the
execution and delivery of this Agreement, the Company covenants and agrees as to
itself and its Subsidiaries that, after the date hereof and prior to the
Effective Time (unless Parent shall otherwise consent in writing (such consent
not to be unreasonably withheld or delayed) and except as otherwise expressly
contemplated by this Agreement and the Stock Option Agreement):
-38-
<PAGE>
(a) the business of it and its Subsidiaries shall be
conducted, in all material respects, in the ordinary and usual course and, to
the extent consistent therewith, it and its Subsidiaries shall use their
respective commercially reasonable best efforts to preserve its business
organization substantially intact and substantially maintain its existing
relations and goodwill with customers, suppliers, distributors, creditors,
lessors, employees and business associates;
(b) it shall not (i) issue, sell, pledge, dispose of or
encumber any capital stock owned by it in any of its Subsidiaries; (ii) amend
its certificate or bylaws or amend, modify or terminate the Rights Agreement,
except as set forth in Section 5.1(s) hereof; (iii) split, combine or reclassify
its outstanding shares of capital stock; (iv) declare, set aside or pay any
dividend payable in cash, stock or property in respect of any capital stock, or
(v) repurchase, redeem or otherwise acquire, except in connection with the Stock
Plans, or permit any of its Subsidiaries to purchase or otherwise acquire, any
shares of its capital stock or any securities convertible into or exchangeable
or exercisable for any shares of its capital stock;
(c) neither it nor any of its Subsidiaries shall (i) issue,
sell, pledge, dispose of or encumber any shares of, or securities convertible
into or exchangeable or exercisable for, or options, warrants, calls,
commitments or rights of any kind to acquire, any shares of its capital stock of
any class or any Voting Debt or any other property or assets (other than (A) the
issuance of Shares pursuant to options outstanding on the date of this Agreement
under the Stock Plans, (B) the issuance of Shares pursuant to the exercise of
Warrants set forth on Schedule 5.1(b), (C) the issuance of 12% Senior
Convertible Notes upon exercise of Warrant Notes outstanding on the date of this
Agreement, (D) the issuance of warrants for Shares upon redemption of
Convertible Notes outstanding on the date of this Agreement and (E) the issuance
of Shares upon conversion of Convertible Notes outstanding on the date of this
Agreement; (ii) other than in the ordinary and usual course of business,
transfer, lease, license, guarantee, sell, mortgage, pledge, dispose of or
encumber any other property or assets (including capital stock of any of its
Subsidiaries) or incur or modify any material indebtedness or other liability;
or (iii) make any commitments for, make or
-39-
<PAGE>
authorize any capital expenditures other than in the amounts set forth with
respect to particular items in the Budget or, by any means, make any acquisition
of, or investment in, assets or stock of any other Person or entity;
(d) Except as may be required by existing contractual
commitments, existing corporate policy with respect to severance or termination
pay or as required by applicable law, neither it nor any of its Subsidiaries
shall (i) enter into any new agreements or commitments for any severance or
termination pay to, or enter into employment or severance agreement with, any of
its directors, officers or employees, or (ii) terminate, establish, adopt, enter
into, make any new grants or awards under, amend or otherwise modify, any
Compensation and Benefit Plans or increase or accelerate the salary, wage, bonus
or other compensation of any employees, officers or directors (except for
increases in salaries, wages and cash bonuses of nonexecutive employees made in
the ordinary course of business consistent with past practice) or pay or agree
to pay any pension, retirement allowance or other employee benefit not required
by any existing Compensation and Benefit Plan;
(e) neither it nor any of its Subsidiaries shall settle or
compromise any material claims or litigation or modify, amend or terminate any
of its material Contracts or waive, release or assign any material rights or
claims;
(f) neither it nor any of its Subsidiaries shall make any Tax
election or permit any insurance policy naming it as a beneficiary or
loss-payable payee to be canceled or terminated except in the ordinary and usual
course of business;
(g) except as may be required as a result of a change in law
or in generally accepted accounting principles, neither it nor any of its
Subsidiaries shall change any of the accounting practices or principles used by
it;
(h) neither it nor any of its Subsidiaries shall adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation,
restructuring, recapitalization, or other reorganization of the Company or any
of its subsidiaries not constituting an inactive Subsidiary (other than the
Merger);
-40-
<PAGE>
(i) neither it nor any of its Subsidiaries shall knowingly
take any action, or knowingly fail to take any action, that is reasonably likely
to jeopardize the treatment of the Merger as a "pooling of interests" for
accounting purposes or as a "reorganization" within the meaning of Section
368(a) of the Code or that would cause any of its representations and warranties
herein to be or become untrue in any material respect;
(j) it shall not suffer or permit expenditures made or
incurred by the Company and its Subsidiaries for any period to materially exceed
the Projected Expenses for such period except for expenses incurred in
connection with the transactions contemplated by this Agreement; and
(k) neither it nor any of its Subsidiaries will offer to, or
enter into an agreement to, do any of the foregoing.
6.2. Conduct of Business of Parent. Parent covenants and
agrees as to itself and its Subsidiaries that, after the date hereof and prior
to the Effective Time (unless the Company shall otherwise consent in writing
(such consent not to be unreasonably withheld or delayed) and except as
otherwise expressly contemplated by this Agreement and the Stock Option
Agreement):
(a) it shall not amend the terms of the Parent Common Stock;
(b) it shall not acquire or agree to acquire, by merging or
consolidating with, or by purchasing a substantial portion of the assets of, or
by any other manner, any business of any corporation, partnership, joint
venture, association or other business organization or division thereof, or
otherwise acquire or agree to acquire, or dispose of or agree to dispose of, any
assets of any person, which, in each case, could reasonably be expected to delay
materially the consummation of, or increase materially the risk of
non-consummation of, the transaction contemplated by this Agreement;
(c) except as may be required as a result of a change in law
or in generally accepted accounting principles, it shall not change, in any
material respect, any of the accounting practices or principles used by it;
-41-
<PAGE>
(d) it shall not knowingly take any action that would result
in a failure of Parent Common Stock to be listed on the NYSE;
(e) neither it nor any of its Subsidiaries shall knowingly
take any action, or knowingly fail to take any action, that is reasonably likely
to jeopardize the treatment of the Merger as a "pooling of interests" for
accounting purposes or as a "reorganization" within the meaning of Section
368(a) of the Code or that would cause any of its representations and warranties
herein to be or become untrue in any material respect; and
(f) neither it nor any of its Subsidiaries will offer to, or
enter into any agreement to, do any of the foregoing.
6.3. Acquisition Proposals. The Company shall, and shall cause
its nonstockholder affiliates and the officers, directors and employees of the
Company and its subsidiaries to, and shall instruct its stockholder affiliates
and the representatives and agents of the Company and its subsidiaries
(including, without limitation, any investment banker, attorney or accountant
retained by the Company or any of its subsidiaries) to, immediately cease and
terminate any existing activities, discussions or negotiations, if any, with any
parties conducted heretofore with respect to any acquisition or exchange of all
or any material portion of the assets of, or more than 15% of the equity
interest in, the Company or any of its Subsidiaries (by direct purchase from the
Company, tender or exchange offer or otherwise) or any business combination,
merger or similar transaction (including an exchange of stock or assets) with or
involving the Company or any Subsidiary or division of the Company (an
"Acquisition Transaction"), other than the Merger. Except as set forth in this
Section 6.2, the Company shall not, and shall cause its nonstockholder
affiliates and the officers, directors and employees of the Company and its
subsidiaries not to, and shall instruct its stockholder affiliates and the
representatives and agents of the Company and its subsidiaries (including,
without limitation, any investment banker, attorney or accountant retained by
the Company or any of its subsidiaries) not to, directly or indirectly,
knowingly encourage, solicit, participate in or initiate discussions or
negotiations with, or provide any information or data (other than the Company's
standard public
-42-
<PAGE>
information package) to, any corporation, partnership, person or other entity or
group (other than Parent and Merger Sub, any affiliate or associate of Parent
and Merger Sub or any designees of Parent and Merger Sub) with respect to any
inquiries or the making of any offer or proposal (including, without limitation,
any offer or proposal to the stockholders of the Company) concerning an
Acquisition Transaction (an "Acquisition Proposal") or otherwise knowingly
facilitate any effort or attempt to make or implement an Acquisition Proposal;
provided, however, that prior to the receipt of the Company Requisite Vote the
Company may furnish information and access, but only in response to a request
for information or access, to any person or entity making a bona fide written
Acquisition Proposal to the board of directors of the Company after the date
hereof which was not knowingly encouraged, solicited or initiated by the Company
or any of its affiliates or any director, employee, representative or agent of
the Company or any of its subsidiaries (including, without limitation, any
investment banker, attorney or accountant retained by the Company or any of its
subsidiaries) on or after the date hereof and may participate in discussions and
negotiate with such person or entity concerning any such Acquisition Proposal
and authorize the Company, subject to compliance with Section 8.3(a), to enter
into a binding written agreement concerning a Superior Proposal (as defined
below), if and only if, in any such case, (i) the board of directors of the
Company determines in good faith, (A) taking into account the written, reasoned
advice of outside counsel to the Company to the effect that failing to provide
such information or access or to participate in such discussions or negotiations
or so to authorize, as the case may be, is reasonably likely to constitute a
breach of such board's fiduciary duties under applicable law, that failing to
provide such information or access or to participate in such discussions or
negotiations or to so authorize, as the case may be, would constitute a breach
of such board's fiduciary duties under applicable law, and (B) taking into
account the written advice of financial advisors to the Company to such effect,
that such Acquisition Proposal, if accepted, is reasonably likely to be
consummated, taking into account all legal, financial and regulatory aspects of
the proposal and the person or entity making the proposal and would, if
consummated, result in a transaction more favorable to the Company's
stockholders from a financial point of view than the transaction contemplated by
this Agreement (any such more favorable Acquisition Proposal as to which both of
the
-43-
<PAGE>
determinations referred to in subclauses (A) and (B) of this clause (i) have
been made being referred to in this Agreement as a "Superior Proposal"), and
(ii) the board of directors of the Company receives from the person or entity
making such bona fide written Acquisition Proposal an executed confidentiality
agreement the terms of which are (without regard to the terms of such
Acquisition Proposal) (A) no less favorable to the Company, and (B) no less
restrictive to the person or entity making such bona fide written Acquisition
Proposal than those contained in the Confidentiality Agreement, dated as of May
21, 1999, referring to Parent as the "Recipient" (the "Company Confidentiality
Agreement"), between the Company and Parent. Nothing in this Agreement shall
prohibit the Board of Directors of the Company from, to the extent applicable,
complying with Rule 14e-2 promulgated under the Exchange Act with regard to an
Acquisition Proposal. The Company will notify Parent within 36 hours if any such
inquiries or proposals are received by, any such information is requested from,
or any such negotiations or discussions are sought to be initiated or continued
with the Company and shall in such notice indicate the identity of the offeror
and the terms and conditions of any such proposal and thereafter shall keep
Parent informed, on a current basis, of the status and terms of such proposals
and the status of such negotiations or discussions, providing copies to Parent
of any Acquisition Proposals made in writing. The Company shall provide Parent
with five days' advance notice of its intention to enter into any agreement with
or to provide any information to any person or entity making any such inquiry or
proposal. The Company agrees not to release any third party from, or waive any
provisions of, any confidentiality or standstill agreement to which the Company
is a party. The Company will inform the individuals or entities referred to in
the first sentence of this Section 6.3 of the obligations undertaken in this
Section 6.3. The Company also will promptly request each person or entity which
has executed, within 36 months prior to the date of this Agreement, a
confidentiality agreement in connection with its consideration of acquiring the
Company to return or destroy all confidential information heretofore furnished
to such person or entity by or on behalf of the Company.
6.4. Information Supplied. Each of the Company and Parent
agrees, as to itself and its Subsidiaries, that none of the information supplied
or to be supplied by it or its Subsidiaries for inclusion or incorporation by
reference
-44-
<PAGE>
in (i) the Registration Statement on Form S-4 to be filed with the SEC by Parent
in connection with the issuance of shares of Parent Common Stock in the Merger
(including the proxy statement and prospectus (the "Prospectus/Proxy Statement")
constituting a part thereof) (the "Registration Statement") will, at the time
the Registration Statement becomes effective under the Securities Act, contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, and (ii)
the Prospectus/Proxy Statement and any amendment or supplement thereto will, at
the date of mailing to stockholders and at the times of the meetings of
stockholders of the Company to be held in connection with the Merger, contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading.
6.5. Stockholders Meeting. The Company will take, in
accordance with applicable law and its certificate of incorporation and bylaws,
all action necessary to convene a meeting of holders of Shares (the
"Stockholders Meeting") as promptly as reasonably practicable after the
Registration Statement is declared effective to consider and vote upon the
adoption of this Agreement. Subject to fiduciary obligations under the DGCL, the
board of directors of the Company shall recommend such adoption and the Company
shall use its reasonable best efforts to solicit such adoption.
6.6. Filings; Other Actions; Notification. (a) Parent and the
Company shall promptly prepare and file with the SEC the Prospectus/Proxy
Statement, and Parent shall prepare and file with the SEC the Registration
Statement, as promptly as practicable. Parent and the Company shall use their
commercially reasonable best efforts to cause the Registration Statement to be
declared effective under the Securities Act as promptly as practicable after
such filing, and promptly thereafter mail the Prospectus/Proxy Statement to the
stockholders of the Company. Parent shall also use its commercially reasonable
best efforts to obtain prior to the effective date of the Registration Statement
all necessary state securities law or "blue sky" permits and approvals required
in connection with the Merger and the consummation of the other transactions
-45-
<PAGE>
contemplated by this Agreement and the Stock Option Agreement and will pay all
expenses incident thereto.
(b) The Company shall use its commercially reasonable best
efforts to cause to be delivered to Parent and its directors a letter of its
independent auditors, dated (i) the date on which the Registration Statement
shall become effective and (ii) the third business day prior to the Effective
Time, and addressed to Parent and its directors, in form and substance customary
for "comfort" letters delivered by independent public accountants in connection
with registration statements similar to the Registration Statement.
(c) The Company and Parent shall cooperate with each other and
use (and shall cause their respective Subsidiaries to use) their respective
commercially reasonable best efforts to take or cause to be taken all actions,
and do or cause to be done all things, necessary, proper or advisable under this
Agreement, the Stock Option Agreement, the Voting Agreement and applicable Laws
to consummate and make effective the Merger and the other transactions
contemplated by this Agreement, the Stock Option Agreement and the Voting
Agreement as soon as practicable, including preparing and filing as promptly as
practicable all documentation to effect all necessary applications, notices,
petitions, filings and other documents and to obtain as promptly as practicable
all permits, consents, approvals and authorizations necessary or advisable to be
obtained from any third party and/or any Governmental Entity in order to
consummate the Merger or any of the other transactions contemplated by this
Agreement, the Stock Option Agreement and the Voting Agreement. In particular,
the Company and Parent each agree to use commercially reasonable efforts to
take, or cause to be taken, all appropriate action, and do, or cause to be done,
such things as may be necessary under federal or state securities laws or the
HSR Act or Foreign Merger Laws (as hereinafter defined) applicable to or
necessary for, and will file as soon as reasonably practicable and, if
appropriate, use commercially reasonable efforts to have declared effective or
approved, all documents and notifications with the SEC and other governmental or
regulatory bodies (including, without limitation, the FDA and equivalent foreign
regulatory bodies, and other foreign regulatory bodies that administer Foreign
Merger Laws, and any foreign labor councils or bodies as may be required) that
they deem necessary or
-46-
<PAGE>
appropriate for, the consummation of the Merger or any of the other transactions
contemplated hereby, and each party shall give the other information reasonably
requested by such other party pertaining to it and its subsidiaries and
affiliates to enable such other party to take such actions. Although the parties
do not anticipate any legislative, administrative or judicial objection to the
consummation of the Merger or any of the transactions contemplated by this
Agreement, each of the Company, Parent and Merger Sub agrees to use commercially
reasonable efforts to contest and resist any action, including legislative,
administrative or judicial action, and to have vacated, lifted, reversed or
overturned any decree, judgment, injunction or other order (whether temporary,
preliminary or permanent) that is in effect and that restricts, prevents or
prohibits the consummation of the Merger or any of the other transactions
contemplated by this Agreement, including, without limitation, by pursuing
available avenues of administrative and judicial appeal. Each of the Company,
Parent and Merger Sub also agrees to use commercially reasonable efforts to take
any and all actions necessary to avoid or eliminate each and every impediment
under any antitrust law that may be asserted by any governmental antitrust
authority or any other party so as to enable the parties to close by the date
specified in Section 8.2(i) the transactions contemplated hereby; provided,
however, that nothing in this Section 6.6 shall require, or be construed to
require, Parent to proffer to, or agree to, sell or hold separate and agree to
sell, before or after the Effective Time, any assets, businesses, or interest in
any assets or businesses of Parent, the Company or any of their respective
affiliates (or to consent to any sale, or agreement to sell, by the Company of
any of its assets or businesses) or to agree to any material changes or
restriction in the operations of any such assets or businesses; and provided,
further, that nothing in this Section 6.6 shall require, or be construed to
require, a proffer or agreement that would, in the good faith judgment of
Parent, be reasonably likely to have a significant adverse effect on the
benefits to Parent of the transactions contemplated by this Agreement. Subject
to applicable Laws relating to the exchange of information, Parent and the
Company shall have the right to review in advance, and to the extent practicable
each will consult the other on, all the information relating to Parent or the
Company, as the case may be, and any of their respective Subsidiaries, that
appear in any filing made with, or written materials submitted to, any third
party and/or any Governmental Entity
-47-
<PAGE>
in connection with the Merger and the other transactions contemplated by this
Agreement, the Stock Option Agreement and the Voting Agreement. In exercising
the foregoing right, each of the Company and Parent shall act reasonably and as
promptly as practicable.
(d) The Company and Parent each shall, upon request by the
other, furnish the other with all information concerning itself, its
Subsidiaries, directors, officers and stockholders and such other matters as may
be reasonably necessary or advisable in connection with the Prospectus/Proxy
Statement, the Registration Statement or any other statement, filing, notice or
application made by or on behalf of Parent, the Company or any of their
respective Subsidiaries to any third party and/or any Governmental Entity in
connection with the Merger and the transactions contemplated by this Agreement,
the Stock Option Agreement and the Voting Agreement.
(e) The Company and Parent each shall keep the other apprised
of the status of matters relating to completion of the transactions
contemplated hereby, including promptly furnishing the other with copies of
notice or other communications received by Parent or the Company, as the case
may be, or any of its Subsidiaries, from any third party and/or any Governmental
Entity with respect to the Merger and the other transactions contemplated by
this Agreement, the Stock Option Agreement and the Voting Agreement. The Company
and Parent each shall give prompt notice to the other of any change that has
resulted in or is reasonably likely to result in a Company Material Adverse
Effect or Parent Material Adverse Effect, respectively.
(f) Parent shall notify the Company promptly (i) of the
receipt of the comments of the SEC, (ii) of any request by the SEC for
amendments or supplements to the Registration Statement, (iii) of the time when
the Registration Statement has become effective or any supplement or amendment
has been filed, or the issuance of any stop order and (iv) of the suspension of
the qualification of the Parent Common Stock issuable in connection with the
Merger for offering or sale in any jurisdiction, and shall supply the Company
with copies of all correspondence with the SEC with respect to the Registration
Statement.
-48-
<PAGE>
(g) If at any time prior to the Effective Time, any event or
circumstance relating to the Company, any Subsidiary, or the Company's or any
Subsidiary's officers or directors should occur and be discovered by the Company
that is required to be described in an amendment or supplement to the definitive
Proxy Statement/Prospectus or the Registration Statement, the Company shall
promptly inform Parent. If at any time prior to the Effective Time, any event or
circumstance relating to Parent or any of its subsidiaries or their respective
officers or directors should occur and be discovered by Parent that is required
to be described in an amendment or supplement to the definitive Proxy
Statement/Prospectus or the Registration Statement, Parent shall promptly inform
the Company. Whenever any event occurs that should be described in an amendment
of, or supplement to, the definitive Proxy Statement/Prospectus or the
Registration Statement, the Company or Parent, as the case may be, shall, upon
learning of such event, promptly notify the other and consult and cooperate with
the other in connection with the preparation of a mutually acceptable amendment
or supplement. The parties shall promptly file such amendment or supplement with
the SEC and mail such amendment or supplement as soon as practicable after it is
cleared by the SEC. No amendment or supplement to the Proxy Statement/Prospectus
or the Registration Statement will be made by Parent or the Company without the
approval of the other party (such approval not to be unreasonably withheld or
delayed).
(h) The Company will use its commercially reasonable best
efforts to obtain, as soon as practicable prior to the Effective Time, the
consents and waivers required under the Contracts listed in Schedule 5.1(d)(ii)
in connection with the consummation of the transactions contemplated by this
Agreement and the Stock Option Agreement.
(i) The Company will periodically provide Parent with current
draft versions of any filings to be made by the Company subsequent to the date
hereof pursuant to the Securities Act or the Exchange Act, including any
documents incorporated therein by reference, promptly after preparation of such
draft.
6.7. Taxation and Accounting. (a) At or prior to the filing of
the Registration Statement and at or prior to the Closing, the Company and
Parent shall execute and
-49-
<PAGE>
deliver to Cooley Godward LLP and to Sullivan & Cromwell tax representation
letters reasonably satisfactory to such counsel setting forth customary
representations which may be relied upon by such counsel in rendering any
opinions contemplated by this Agreement. Parent shall use commercially
reasonable efforts to cause Sullivan & Cromwell to deliver to Parent a legal
opinion, satisfying the requirements of Item 601 of Regulation S-K promulgated
under the Securities Act and dated as of a date that is no more than two
business days prior to the date of filing of the Registration Statement, to the
effect that the Merger will constitute a reorganization within the meaning of
Section 368(a) of the Code, based in part on the tax representation letters
described in this Section 6.7(a). The Company shall use commercially reasonable
efforts to cause Cooley Godward LLP to deliver to the Company a legal opinion,
satisfying the requirements of Item 601 of Regulation S-K promulgated under the
Securities Act and dated as of a date that is no more than two business days
prior to the date of filing of the Registration Statement, to the effect that
the Merger will constitute a reorganization within the meaning of Section 368(a)
of the Code, based in part on the tax representation letters described in this
Section 6.7(a).
(b) Parent shall cooperate with the Company and the Company
shall use reasonable best efforts to cause to be delivered to Parent and the
Company, a letter from Ernst & Young LLP addressed to the Company, as of the
Closing Date, stating that based upon discussions with officials of the Company
responsible for financial and accounting matters, and information furnished to
Ernst & Young LLP to the date of its letter, Ernst & Young LLP concurs with the
Company's management's conclusion that, as of the date of its letter, no
conditions exist related to the Company that would preclude Parent's accounting
for the Merger as a pooling of interests.
(c) The Company shall cooperate with Parent and Parent shall
use reasonable best efforts to cause to be delivered to Parent, a letter from
PricewaterhouseCoopers LLP addressed to Parent, dated as of the Closing Date,
confirming as of the Closing Date that, based upon discussions with officials of
Parent responsible for financial and accounting matters and the letter provided
by Ernst & Young LLP to the Company, PricewaterhouseCoopers LLP concurs with
Parent management's conclusions that the Merger
-50-
<PAGE>
will qualify as a pooling of interests transaction under Opinion 16 of the
Accounting Principles Board and applicable SEC rules and regulations.
6.8. Access. Upon reasonable notice, and except as may
otherwise be required by applicable law, each of the Company and Parent shall
(and shall cause its Subsidiaries to) afford the other's officers, employees,
counsel, accountants and other authorized representatives ("Representatives")
access, during normal business hours throughout the period prior to the
Effective Time, to its properties, books, contracts, records, personnel and
advisors and, during such period, each shall (and shall cause its Subsidiaries
to) furnish promptly to the other all documents, data and information concerning
its business, properties (tangible and intangible) and personnel as may
reasonably be requested. The Company and Parent shall provide access to the
information described above regardless of whether or not such documents, data
and information are or may be covered by the attorney-client privilege, lawyer's
work product privilege or other privileges against disclosure, as the parties
have concluded that such disclosure shall not constitute a waiver of the
attorney-client or any other privilege due to the substantially identical
interest of the Company and Parent with respect to such information. No
investigation pursuant to this Section shall affect or be deemed to modify any
representation or warranty made by the Company, Parent or Merger Sub. No
provision of this Agreement shall require the Company or Parent to permit any
inspection, or to disclose any information, that in the reasonable judgment of
the Company or the Parent, as the case may be, would result in the disclosure of
any trade secrets of third parties or violate any of its obligations to third
parties with respect to confidentiality if the Company or Parent, as the case
may be, shall have used reasonable efforts to obtain the consent of such third
party to such inspection or disclosure. All requests for information made
pursuant to this Section shall be directed to an executive officer of the
Company or Parent, as the case may be, or such Person as may be designated by
either of its officers. All such information shall be subject to the Company
Confidentiality Agreement and the Confidentiality Agreement, dated as of May 21,
1999, referring to the Company as the Recipient (the "Parent Confidentiality
Agreement"), between the Company and Parent, as the case may be.
-51-
<PAGE>
6.9. Affiliates. (i) Prior to the Effective Time, Parent shall
deliver to the Company a list of names and addresses of those Persons who are,
in the opinion of Parent, as of the time of the Stockholders Meeting referred to
in Section 6.5, "affiliates" of the Company within the meaning of Rule 145 under
the Securities Act and for the purposes of applicable interpretations regarding
the pooling of interests method of accounting. The Company shall provide to
Parent such information and documents as Parent shall reasonably request for
purposes of such list. There shall be added to such list the names and addresses
of any other Person the Company later identifies as an affiliate of the Company
or Parent reasonably identifies (by written notice to the Company within ten
business days after the Company's receipt of such list) as being a Person who
may be deemed to be such an affiliate of the Company; provided, however, that no
such Person identified by Parent shall be added to the list of affiliates of the
Company if Parent shall receive from the Company, on or before the date of the
Stockholders Meeting, an opinion of counsel reasonably satisfactory to Parent to
the effect that such Person is not an affiliate. The Company shall use
reasonable efforts to deliver or cause to be delivered to Parent, prior to the
date of the Stockholders Meeting, (i) from each of such affiliates of the
Company identified in the foregoing list (as the same may be supplemented as
aforesaid), other than AstraZeneca plc, a letter dated as of the Closing Date
substantially in the form attached as Exhibit A-1 (the "Company Affiliates
Letter"), and (ii) from AstraZeneca plc a letter dated as of the Closing Date
substantially in the form attached as Exhibit AZ-1 (the "AstraZeneca Affiliate
Letter").
(ii) Parent shall use reasonable efforts to obtain from each
of those Persons who are, in the opinion of Parent, "affiliates" of Parent
within the meaning of Rule 145 under the Securities Act and for the purposes of
applicable interpretations regarding the pooling of interests method of
accounting a letter dated as of the Closing Date substantially in the form
attached as Exhibit A-2 (the "Pooling Affiliates Letter").
(iii) If the Merger would otherwise qualify for pooling of
interests accounting treatment, shares of Parent Common Stock issued to such
affiliates of the Company in exchange for Shares shall not be transferable until
such time as financial results covering at least 30 days of
-52-
<PAGE>
combined operations of Parent and the Company have been published within the
meaning of Section 201.01 of the SEC's Codification of Financial Reporting
Policies, regardless of whether each such affiliate has provided the written
agreement referred to in this Section, except to the extent permitted by, and in
accordance with, Accounting Series Release 135 and Staff Accounting Bulletins 65
and 76. Any Shares held by such affiliates shall not be transferable, regardless
of whether each such affiliate has provided the written agreement referred to in
this Section, if such transfer, either alone or in the aggregate with other
transfers by affiliates, would preclude Parent's ability to account for the
business combination to be effected by the Merger as a pooling of interests. The
Company shall not register the transfer of any Certificate, unless such transfer
is made in compliance with the foregoing.
6.10. Listing; De-registration. Parent shall use its best
efforts to cause the shares of Parent Common Stock to be issued in the Merger to
be approved for listing on the NYSE subject to official notice of issuance,
prior to the Closing Date. The Company shall use its best efforts to cause the
Shares to be de-registered from the Nasdaq National Market and de-registered
under the Exchange Act as soon as practicable following the Effective Time.
6.11. Publicity. Parent shall control and coordinate the press
relations and publicity activities of the parties in connection with the Merger.
The Company shall consult with Parent with respect to issuing any press releases
or otherwise making public announcements with respect to the Merger and the
other transactions contemplated by this Agreement, the Voting Agreement and the
Stock Option Agreement and will not issue any press releases or otherwise make
any public announcements with respect thereto without Parent's prior consent
(which consent shall not be unreasonably withheld), except as may be required by
law or pursuant to the Company's listing agreement with or rules of the Nasdaq
National Market.
6.12. Benefits.
(a) Stock Options.
(i) At the Effective Time, each outstanding Company Option
under the Stock Plans, whether vested or unvested, shall be deemed to constitute
an option to acquire
-53-
<PAGE>
(a "New Parent Option"), on the same terms and conditions as were applicable
under such Company Option, the same number of shares of Parent Common Stock
(rounded to the nearest whole number) as the holder of such Company Option would
have been entitled to receive pursuant to the Merger had such holder exercised
such option in full immediately prior to the Effective Time, at an exercise
price per share (rounded to the nearest whole cent) equal to (y) the aggregate
exercise price for the Shares otherwise purchasable pursuant to such Company
Option divided by (z) the number of full shares of Parent Common Stock deemed
purchasable pursuant to such Company Option in accordance with the foregoing;
provided, however, that in the case of any Company Option to which Section 422
of the Code applies, the option price, the number of shares purchasable pursuant
to such option and the terms and conditions of exercise of such option shall be
determined in accordance with the foregoing, subject to such adjustments as are
necessary in order to satisfy the requirements of Section 424(a) of the Code. At
or prior to the Effective Time, the Company shall take all necessary actions to
permit the assumption of the unexercised Company Options by Parent pursuant to
this Section.
(ii) Effective at the Effective Time, Parent shall assume, as
a New Parent Option, each outstanding Company Option in accordance with this
Section and with the terms of the Stock Plan under which it was issued and the
stock option agreement by which it is evidenced. Not later than ten calendar
days after the Closing Date, Parent shall file a registration statement under
the Securities Act of 1933 on Form S-8, or other appropriate form, covering
shares of Parent Common Stock subject to such New Parent Options.
(b) Employee Benefits. Parent agrees that during the period
commencing at the Effective Time and ending on the first anniversary thereof,
the Employees will continue to be provided with benefits under employee benefit
plans (other than stock options or other plans involving the issuance of
securities of the Company or Parent) which in the aggregate are substantially
comparable to those currently provided by the Company to such Employees;
provided, however, that Employees covered by collective bargaining agreements
need not be provided with such benefits. Parent will cause each employee benefit
plan of Parent in which Employees are eligible to participate to take into
account for purposes of eligibility and vesting
-54-
<PAGE>
thereunder the service of such Employees with the Company as if such service
were with Parent, to the same extent that such service was credited under a
comparable plan of the Company. Parent will, and will cause the Surviving
Corporation to, honor in accordance with their terms (i) all employee benefit
obligations to current and former Employees accrued as of the Effective Time and
(ii) to the extent set forth on Schedule 5.1(h)(i), all employee severance plans
in existence on the date hereof and all employment or severance agreements
entered into prior to the date hereof.
6.13. Expenses. The Surviving Corporation shall pay all
charges and expenses, including those of the Exchange Agent, in connection with
the transactions contemplated in Article IV, and Parent shall reimburse the
Surviving Corporation for such charges and expenses. Except as otherwise
provided in Section 8.5(b), whether or not the Merger is consummated, all costs
and expenses incurred in connection with this Agreement, the Stock Option
Agreement, the Voting Agreement and the Merger and the other transactions
contemplated by this Agreement, the Stock Option Agreement and the Voting
Agreement shall be paid by the party incurring such expense.
6.14. Indemnification; Directors' and Officers' Insurance. (a)
From and after the Effective Time, Parent agrees that it will indemnify, defend
and hold harmless each individual entitled to indemnification as of the
Effective Time under the Company's certificate of incorporation and bylaws as in
effect on the date of this Agreement (the "Indemnified Parties"), against any
costs or expenses (including reasonable attorneys' fees), judgments, fines,
losses, claims, damages or liabilities (collectively, "Costs") incurred in
connection with any claim, action, suit, proceeding or investigation, whether
civil, criminal, administrative or investigative, arising out of matters
existing or occurring at or prior to the Effective Time (including transactions
contemplated by this Agreement), whether asserted or claimed prior to, at or
after the Effective Time, to the fullest extent that the Company would have been
permitted under the DGCL and its certificate of incorporation, bylaws and other
agreements (including the Indemnification Agreements referred to below) in
effect on the date hereof to indemnify such Person (and Parent shall also
advance expenses as incurred to the fullest extent permitted under applicable
law, provided the Person to whom expenses are advanced provides an undertaking
to repay such
-55-
<PAGE>
advances if it is ultimately determined that such Person is not entitled to
indemnification).
(b) From and after the Effective Time, Parent will cause the
Surviving Corporation to fulfill and honor in all respects the obligations of
the Company pursuant to each indemnification agreement listed in Schedule
6.14(b).
(c) Any Indemnified Party wishing to claim indemnification
under paragraph (a) of this Section 6.14, upon learning of any such claim,
action, suit, proceeding or investigation, shall promptly notify Parent thereof.
In the event of any such claim, action, suit, proceeding or investigation
(whether arising before or after the Effective Time), (i) Parent or the
Surviving Corporation shall have the right to assume the defense thereof and
Parent shall not be liable to such Indemnified Parties for any legal expenses of
other counsel or any other expenses subsequently incurred by such Indemnified
Parties in connection with the defense thereof unless there is a conflict of
interest between the Indemnified Parties and Parent, in which event Parent shall
be liable to the Indemnified Parties for the fees and expenses of not more than
one firm of counsel, (ii) the Indemnified Parties will cooperate in the defense
of any such matter and (iii) Parent shall not be liable for any settlement
effected without its prior written consent and no Indemnified Party shall be
liable for any settlement effected without its prior written consent unless such
settlement includes a complete release of claims against such Indemnified Party;
and provided, further, that Parent shall not have any obligation hereunder to
any Indemnified Party if and when a court of competent jurisdiction shall
ultimately determine, and such determination shall have become final, that the
indemnification of such Indemnified Party in the manner contemplated hereby is
prohibited by applicable law.
(d) Notwithstanding any contrary provision of this Agreement,
prior to the Effective Time, the Company may purchase insurance coverage
extending for a period of six years the Company's directors' and officers'
liability insurance coverage in effect as of the date hereof (covering past or
future claims with respect to periods prior to and including the Effective
Time); provided that the aggregate premium payable for such insurance shall not
exceed 175% of the last annual premium paid for such coverage prior to the date
hereof.
-56-
<PAGE>
(e) If the Surviving Corporation or any of its successors or
assigns (i) shall consolidate with or merge into any other corporation or entity
and shall not be the continuing or surviving corporation or entity of such
consolidation or merger or (ii) shall transfer all or substantially all of its
properties and assets to any individual, corporation or other entity, then and
in each such case, proper provisions shall be made so that the successors and
assigns of the Surviving Corporation shall assume all of the obligations set
forth in this Section.
(f) The provisions of this Section shall survive the
consummation of the Merger at the Effective Time, are intended to be for the
benefit of, and shall be enforceable by, each of the Indemnified Parties as
intended third party beneficiaries and their heirs and estates and shall be
binding on all successors and assigns of Parent and the Surviving Corporation.
6.15. Other Actions by the Company and Parent.
(a) Rights. Prior to the Effective Time, the board of
directors of the Company shall take all necessary action to ensure that the
representation and warranty in Section 5.1(s) is accurate.
(b) Antitakeover Statutes. If any Antitakeover Statute is or
may become applicable to the Merger or the other transactions contemplated by
this Agreement, the Stock Option Agreement, or the Voting Agreement, each of
Parent and the Company and its board of directors shall grant such approvals and
take such lawful actions as are necessary so that such transactions may be
consummated as promptly as practicable on the terms contemplated by this
Agreement, the Stock Option Agreement or the Voting Agreement or by the Merger
and otherwise act to eliminate or minimize the effects of such statute or
regulation on such transactions.
6.16. Convertible Notes and Warrants. Prior to the Effective
Time, the Company and Parent shall take all action necessary to provide that on
and after the Effective Time the Convertible Notes and Warrants (including the
Note Warrants) will be convertible only into the Merger Consideration, subject
to any holder's right to hold securities through maturity.
-57-
<PAGE>
6.17. Funding Mechanism. Parent and the Company agree as
follows.
(a) Parent agrees to cause one of its wholly owned
subsidiaries (the "Lender") to make available as a loan to the Company, subject
to the provisions of Sections 6.17(b) through (e), (i) $15,000,000 (or such
lesser amount as the Company elects to borrow) on September 1, 1999 (the "First
Loan"), (ii) an additional $10,000,000 (or such lesser amount as the Company
elects to borrow) on November 1, 1999 (the "Second Loan"), and (iii) an
additional $10,000,000 (or such lesser amount as the Company elects to borrow)
on December 31, 1999 (the "Third Loan" and, collectively with the First Loan and
the Second Loan, the "Loans" and each such date, with respect to the Loan to be
made on such date, the "Funding Date" for such Loan).
(b) The Lender shall not be obligated to make any Loan if, on
or prior to the Funding Date for such Loan, there has been a material breach by
the Company of any covenant or agreement of the Company contained in this
Agreement (a "Breach").
(c) The Lender shall not be obligated to make the Second Loan
or the Third Loan if, on or prior to the Funding Date for any such Loan:
(i) The Stockholders Meeting (as defined in the
Merger Agreement) shall have been convened and the adoption referred to
in Section 7.1(a) shall not have been obtained thereat or at any
adjournment or postponement thereof (a "Vote Failure"), or
(ii) The Company shall have terminated this
Agreement, other than pursuant to Section 8.2(i), 8.2(iii) or 8.3(b)
thereof (a "Company Termination").
(d) Unless the Lender and the Company agree otherwise, each
Loan will mature on a date (which date shall not be later than the fifth
anniversary of the Funding Date for such Loan) determined in accordance with
Section 6.17(e). The maturity date of each Loan will accelerate to the first
anniversary of the Funding Date for such Loan in the event of a Breach, a Vote
Failure or a Company Termination.
-58-
<PAGE>
(e) The parties agree that the terms and conditions of, and
the definitive documentation concerning the Loans (the "Terms") shall be
reasonable and customary in light of the Company's creditworthiness, business
prospects and industry. Parent and the Company agree to negotiate in good faith
concerning the Terms and the consents, waivers and approvals necessary or
appropriate in connection with the funding of the Loans on and subject to the
Terms (such consents, waivers and approvals, the "Waivers").
(f) The Terms and Waivers will be determined, if possible, by
the mutual agreement of Parent and the Company. If Parent and the Company are
unable to reach such an agreement by July 15, 1999, Parent and the Company shall
jointly designate an individual or entity to determine no later than August 15,
1999 the Terms and Waivers after due consideration of this Section 6.17 and any
submissions the Company and Parent choose to make to such individual or entity,
and the decision of such person or entity shall be final and binding upon the
parties. If Parent and the Company are unable to mutually agree on an individual
or entity by July 15, 1999, each shall choose an investment banking firm (other
than Goldman, Sachs & Co. and Lehman Brothers Inc.) and the two firms so chosen
shall select an individual or entity which shall determine the Terms and
Waivers, which determination shall be final and binding on the parties. If
either Parent or the Company fails to select an investment banking firm within
five calendar days of receipt of a notice specifying such failure from such
other party, such other party may select an individual or entity which shall
determine the Terms and Waivers, which determination shall be final and binding
on the parties.
ARTICLE VII
Conditions
7.1. Conditions to Each Party's Obligation to Effect the
Merger. The respective obligation of each party to effect the Merger is subject
to the satisfaction or waiver at or prior to the Closing of each of the
following conditions:
(a) Stockholder Approval. This Agreement shall have been duly
adopted by holders of Shares constituting the Company Requisite Vote.
-59-
<PAGE>
(b) Regulatory Consents. The waiting period applicable to the
consummation of the Merger under the HSR Act shall have expired or been
terminated.
(c) Litigation. No court or Governmental Entity of competent
jurisdiction shall have enacted, issued, enforced or entered any statute, rule,
regulation, judgment, decree, injunction or other order (whether temporary,
preliminary or permanent) that is in effect and restrains, enjoins or otherwise
prohibits consummation of the transactions contemplated by this Agreement
(collectively, an "Order"), and no Governmental Entity shall have instituted any
proceeding seeking any such Order.
(d) Registration Statement. The Registration Statement shall
have become effective under the Securities Act and no stop order suspending the
effectiveness of the Registration Statement shall have been issued and no
proceedings for that purpose shall have been initiated or be threatened overtly
by the SEC.
7.2. Conditions to Obligations of Parent and Merger Sub. The
obligations of Parent and Merger Sub to effect the Merger are also subject to
the satisfaction or waiver by Parent prior to the Effective Time of the
following conditions:
(a) Representations and Warranties. (i) The representations
and warranties of the Company set forth in this Agreement shall be true and
correct in all material respects as of the date of this Agreement, and (ii) the
representations and warranties of the Company set forth in Sections 5.1(b), (c)
and (j) shall be true and correct in all material respects as of the Closing
Date as though made on and as of the Closing Date, and (iii) the representations
and warranties of the Company set forth in this Agreement (other than the
representations and warranties of the Company set forth in Sections 5.1(b), (c)
and (j)), considered without regard to any qualification by, or references to,
"material," "in all material respects" or "Company Material Adverse Effect,"
shall be true and correct as of the Closing Date as though made on the Closing
Date, except for such failures of such representations and warranties to be true
and correct as do not arise from events, occurrences or matters that,
individually and in the aggregate, have not had and are not reasonably likely to
have a Company Material Adverse Effect, and (iv) Parent
-60-
<PAGE>
shall have received a certificate signed on behalf of the Company by the chief
executive officer and chief financial officer of the Company to the effect of
the foregoing.
(b) Performance of Obligations of the Company. The Company
shall have performed in all material respects all obligations required to be
performed by it under this Agreement and the Stock Option Agreement at or prior
to the Closing Date, and Parent shall have received a certificate signed on
behalf of the Company by the chief executive officer and chief financial officer
of the Company to such effect.
(c) Regulatory Consents. Other than the filing provided for in
Section 1.3, all filings required to be made prior to the Effective Time by the
Company or any of its Subsidiaries, with, and all consents, approvals and
authorizations required to be obtained prior to the Effective Time by, the
Company or any of its Subsidiaries from, any Governmental Entity in connection
with the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby by the Company shall have been made or obtained
(as the case may be), except where the failure to so make or obtain will not
result in either a Company Material Adverse Effect or a Parent Material Adverse
Effect or have a significant adverse effect on the benefits to Parent of the
transactions contemplated by this Agreement.
(d) Consents Under Agreements. The Company shall have obtained
the consent or approval of each Person whose consent or approval shall be
required under each Contract to which the Company or any of its Subsidiaries is
a party, except those for which the failure to obtain such consent or approval,
individually or in the aggregate, is not reasonably likely to have a Company
Material Adverse Effect, is not reasonably likely to materially adversely affect
the ability of the Company to consummate the transactions contemplated by this
Agreement and is not reasonably likely to impair the ability of the Parent or
any of their respective affiliates, following consummation of the Merger, to
conduct any material business or operations in any jurisdiction where they are
now being conducted.
(e) Tax Opinion. Parent shall have received the opinion of
Sullivan & Cromwell, counsel to Parent, dated the Closing Date, to the effect
that the Merger will be
-61-
<PAGE>
treated for Federal income tax purposes as a reorganization within the meaning
of Section 368(a) of the Code, and that each of Parent, Merger Sub and the
Company will be a party to that reorganization within the meaning of Section
368(b) of the Code. In rendering such opinion, such counsel may rely on
customary factual representations furnished by the Company, Parent and Merger
Sub.
(f) Rights Agreement. All necessary action shall have been
taken to ensure that neither the entering into of this Agreement nor the
consummation of the Merger will cause the preferred stock purchase rights issued
pursuant to the Rights Agreement to become exercisable, cause Parent to become
an Acquiring Person (as such term is defined in the Rights Agreement), or give
rise to a Distribution Date or a Shares Acquisition Date (as such terms are
defined in the Rights Agreement).
(g) Affiliates Letters. Parent shall have received a Company
Affiliates Letter from each Person identified as an affiliate of the Company
pursuant to Section 6.9(i) (other than AstraZeneca plc) and shall have received
the AstraZeneca Affiliates Letter from AstraZeneca plc.
(h) Accountants' Letters. Parent shall have received the
letters described in Sections 6.7(b) and 6.7(c), unless the failure of Parent to
receive the letter described in Section 6.7(c) has been proximately caused by
Parent's failure to issue or sell shares of Parent Common Stock.
7.3. Conditions to Obligation of the Company. The obligation
of the Company to effect the Merger is also subject to the satisfaction or
waiver by the Company prior to the Effective Time of the following conditions:
(a) Representations and Warranties. (i) The representations
and warranties of Parent and Merger Sub set forth in this Agreement shall be
true and correct in all material respects as of the date of this Agreement, and
(ii) the representations and warranties of Parent and Merger Sub set forth in
Sections 5.2(c) and (d) shall be true and correct in all material respects as of
the Closing Date as though made on and as of the Closing Date, and (iii) the
representations and warranties of Parent and Merger Sub set forth in this
Agreement (other than the representations and
-62-
<PAGE>
warranties of the Company set forth in Sections 5.2(c) and (d)), considered
without regard to any qualification by, or reference to, "material," "in all
material respects" or "Parent Material Adverse Effect," shall be true and
correct as of the Closing Date as though made on the Closing Date, except for
such failures of such representations and warranties to be true and correct as
do not arise from events, occurrences or matters that, individually and in the
aggregate, have not had and are not reasonably likely to have a Parent Material
Adverse Effect, and (iv) the Company shall have received a certificate signed on
behalf of Parent by the chief executive officer and chief financial officer of
Parent to the effect of the foregoing.
(b) Performance of Obligations of Parent and Merger Sub. Each
of Parent and Merger Sub shall have performed in all material respects all
obligations required to be performed by it under this Agreement and the Stock
Option Agreement at or prior to the Closing Date, and the Company shall have
received a certificate signed on behalf of Parent by the chief executive officer
and chief financial officer of Parent to such effect.
(c) Regulatory Consents. All filings required to be made prior
to the Effective Time by Parent or any of its Subsidiaries, with, and all
consents, approvals and authorizations required to be obtained prior to the
Effective Time by, Parent or any of its Subsidiaries from, any Governmental
Entity in connection with the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby by Parent and Merger Sub
shall have been made or obtained (as the case may be), except where the failure
to so make or obtain will not result in either a Company Material Adverse Effect
or a Parent Material Adverse Effect.
(d) Tax Opinion. The Company shall have received the opinion
of Cooley Godward LLP, counsel to the Company, dated the Closing Date, to the
effect that the Merger will be treated for Federal income tax purposes as a
reorganization within the meaning of Section 368(a) of the Code, and that each
of Parent, Merger Sub and the Company will be a party to that reorganization
within the meaning of Section 368(b) of the Code. In rendering such opinion,
such counsel may rely on customary factual representations furnished by the
Company, Parent and Merger Sub.
-63-
<PAGE>
(e) NYSE Listing. The shares of Parent Common Stock to be
delivered pursuant to the Merger shall have been duly authorized for listing on
the NYSE, subject to official notice of issuance.
(f) Accountants' Letters. The Company shall have received the
letter described in Section 6.7(b).
ARTICLE VIII
Termination
8.1. Termination by Mutual Consent. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time, whether before or after the approval by stockholders of the Company
referred to in Section 7.1(a), by mutual written consent of the Company, Parent
and Merger Sub, by action of their respective boards of directors.
8.2. Termination by Either Parent or the Company. This
Agreement may be terminated and the Merger may be abandoned at any time prior to
the Effective Time by action of the board of directors of either Parent or the
Company if (i) the Merger shall not have been consummated by November 30, 1999,
whether such date is before or after the date of approval by the stockholders of
the Company referred to in Section 7.1(a); provided, however, that if a request
for additional information is received from the United States Federal Trade
Commission or the Antitrust Division of the United States Department of Justice
pursuant to the HSR Act or additional information is requested by a governmental
authority (a "Foreign Authority") pursuant to the antitrust, competition,
foreign investment, or similar laws or any foreign countries or supranational
commissions or boards that require pre-merger notifications or filings with
respect to the Merger (collectively, "Foreign Merger Laws"), then such date
shall be extended to the 30th day following certification by Parent and/or the
Company, as applicable, that Parent and/or the Company, as applicable, have
substantially complied with such request, but in any event not later than
January 31, 2000, (ii) the Stockholders Meeting shall have been convened and the
adoption referred to in Section 7.1(a) shall not have been obtained thereat or
at any adjournment or postponement thereof, or (iii) any Order permanently
restraining, enjoining or otherwise
-64-
<PAGE>
prohibiting the Merger shall become final and non-appealable (whether before or
after the adoption referred to in Section 7.1(a)); provided that the right to
terminate this Agreement pursuant to clause (i) above shall not be available to
any party that has breached in any material respect its obligations under this
Agreement in any manner that shall have been the proximate cause of, or resulted
in, the failure to consummate the Merger by the date referred to in clause (i)
of this Section 8.2 and, provided, further, that the right to terminate this
Agreement pursuant to clause (iii) above shall not be available to any party
that has breached its covenant to use commercially reasonable best efforts to
prevent such Order from being issued and to use commercially reasonable best
efforts to cause such Order to be lifted.
8.3. Termination by the Company. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time, whether before or after the approval by stockholders of the Company
referred to in Section 7.1(a), by action of the board of directors of the
Company:
(a) If (i) the Company is not in material breach of any of the
terms of this Agreement, (ii) the board of directors of the Company authorizes
the Company, subject to complying with the terms of this Agreement, to enter
into a binding written agreement concerning a Superior Proposal and the Company
notifies Parent in writing, that it intends to enter into such an agreement,
attaching the most current version of such agreement to such notice, and (iii)
Parent does not make, within five calendar days of receipt of the Company's
written notification of its intention to enter into such an agreement, an offer
that is at least as favorable, from a financial point of view, to the
stockholders of the Company as the Superior Proposal. The Company agrees (x)
that it will not enter into a binding agreement referred to in clause (ii) of
the previous sentence until at least the sixth calendar day after it has
provided the written notice to Parent required thereby and (y) to notify Parent
promptly if its intention to enter into a written agreement referred to in such
notice shall change at any time after giving such notification.
(b) If there has been a material breach by Parent or Merger
Sub of any representation, warranty, covenant or agreement of Parent or Merger
Sub contained in
-65-
<PAGE>
this Agreement such that the conditions in Section 7.3(a) or (b) will not be
satisfied (a "Terminating Parent Breach"); provided, however, that, if such
Terminating Parent Breach is curable by Parent through the exercise of
reasonable best efforts and such cure is reasonably likely to be completed prior
to the applicable date specified in Section 8.2(i), then for so long as Parent
continues to exercise reasonable best efforts to cure such Terminating Parent
Breach, the Company may not terminate this Agreement under this Section 8.3(b).
8.4. Termination by Parent. This Agreement may be terminated
and the Merger may be abandoned at any time prior to the Effective Time by
action of the board of directors of Parent:
(a) If the board of directors of the Company shall have
withdrawn or adversely modified its approval or recommendation of this Agreement
or failed to reconfirm its recommendation of this Agreement within five calendar
days after a written request by Parent to do so.
(b) There has been a material breach by the Company of any
representation, warranty, covenant or agreement of the Company contained in this
Agreement such that the conditions in Section 7.2(a) or (b) will not be
satisfied (a "Terminating Company Breach"); provided, however, that, if such
Terminating Company Breach is curable by the Company through the exercise of
reasonable best efforts and such cure is reasonably likely to be completed prior
to the applicable date specified in Section 8.2(i), then for so long as the
Company continues to exercise reasonable best efforts, Parent may not terminate
this Agreement under this Section 8.4(b).
8.5. Effect of Termination and Abandonment. (a) In the event
of termination of this Agreement and the abandonment of the Merger pursuant to
this Article VIII, this Agreement (other than as set forth in Section 9.1) shall
become void and of no effect with no liability of any party hereto (or any of
its directors, officers, employees, agents, legal and financial advisors or
other representa tives) except pursuant to Section 6.13, Section 6.17, Section
8.5 and Article IX; provided, however, that except as otherwise provided herein,
no such termination shall relieve any party hereto of any liability or damages
resulting from any willful breach of this Agreement.
-66-
<PAGE>
(b) In the event that (i) (A) a bona fide Acquisition Proposal
shall have been made to the Company or any of its Subsidiaries or any of its
stockholders or any Person shall have announced an intention (whether or not
conditional) to make an Acquisition Proposal with respect to the Company or any
of its Subsidiaries, and on or following the date of this Agreement but prior to
the date of the Stockholders Meeting such Acquisition Proposal, announcement or
intention is or becomes publicly known, and (B) on or following the date of this
Agreement and prior to the time such Acquisition Proposal, announcement or
intention is or becomes publicly known, the occurrence of a Parent Material
Adverse Effect shall not have become publicly known, and (C) on or following the
date on which such Acquisition Proposal, announcement or intention is or becomes
publicly known, this Agreement is terminated by either Parent or the Company
pursuant to Section 8.2(ii), or (ii) this Agreement is terminated (x) by the
Company pursuant to Section 8.3(a) or (y) by Parent pursuant to Section 8.4(a),
then, subject to Section 8.5(c), the Company (p) shall promptly, but in no event
later than two days after the date of such termination (except as otherwise
provided in the proviso to this sentence), pay Parent a termination fee of
$16,900,000 payable by wire transfer of same day funds, and (q) shall promptly,
but in no event later than two calendar days after being notified of such by
Parent, pay all of the charges and expenses incurred by Parent or Merger Sub in
connection with this Agreement, the Stock Option Agreement and the Voting
Agreement and the transactions contemplated by this Agreement, the Stock Option
Agreement and the Voting Agreement, up to a maximum of $5,000,000; provided,
however, that no termination fee shall be payable to Parent by reason of Section
8.5(b)(i) or a termination of this Agreement pursuant to Section 8.3(a) unless
and until (I) any person or entity (other than Parent) (an "Acquiring Party")
has acquired, by purchase, merger, consolidation, sale, assignment, lease,
transfer or otherwise, in one transaction or any related series of transactions
within 18 months of such termination, a majority of the voting power of the
outstanding securities of the Company or (II) there has been consummated a
merger, consolidation or similar business combination between the Company and an
Acquiring Party or an affiliate thereof as a result of which the stockholders of
the Company immediately prior to the transaction do not own at least 75% of the
surviving entity. The Company acknowledges that the agreements contained in this
Section 8.5(b) are an integral part of the transactions con-
-67-
<PAGE>
templated by this Agreement, and that, without these agreements, Parent and
Merger Sub would not enter into this Agreement; accordingly, if the Company
fails to promptly pay the amount due pursuant to this Section 8.5(b), and, in
order to obtain such payment, Parent or Merger Sub commences a suit which
results in a judgment against the Company for the fee set forth in this
paragraph (b), the Company shall pay to Parent or Merger Sub its costs and
expenses (including attorneys' fees) in connection with such suit, together with
interest on the amount of the fee at the prime rate of Citibank, N.A. in effect
on the date such payment was required to be made.
(c) Parent agrees that the payment provided for in Section
8.5(b) shall be the sole and exclusive remedy of Parent upon termination of this
Agreement pursuant to Section 8.3(a) or 8.4(a) or (c), as the case may be, and
such remedy shall be limited to the aggregate of the sums stipulated in such
Section 8.5(b); provided, however, that nothing herein shall relieve any party
from liability for the willful breach of any of its representations, warranties,
covenants or agreements set forth in this Agreement. In no event shall the
Company be required to pay to Parent more than one termination fee pursuant to
Section 8.5(b)(p). Notwithstanding any other provision of this Agreement or the
Stock Option Agreement, any termination fee required to be paid to Parent
pursuant to Section 8.5(b)(p) shall be reduced (but not below zero) to the
extent necessary so that the sum of the portion of any termination fee actually
paid to Parent, the aggregate of all Cancellation Amounts (as defined in the
Stock Option Agreement) paid to Parent pursuant to the Stock Option Agreement
and the proceeds actually received by Parent as the result of selling Shares to
a third party which acquires more than 50% of the Company's outstanding voting
securities (other than the Company or any of its affiliates) shall not exceed
$21,900,000. In no event shall (i) the sum of the portion of any termination fee
actually paid to Parent and the cash proceeds actually received by Parent as the
result of selling Shares to a third party which acquires more than 50% of the
Company's outstanding voting securities (other than the Company or any of its
affiliates) exceed $21,900,000, or (ii) the sum of the portion of any
termination fee actually paid to Parent, the aggregate Cancellation Amounts paid
to parent pursuant to the Stock Option Agreement and the cash proceeds actually
received by parent as the result of selling Shares to a third party
-68-
<PAGE>
which acquires more than 50% of the Company' outstanding voting securities
(other than the Company or any of its affiliates) exceed $21,900,000.
ARTICLE IX
Miscellaneous and General
9.1. Survival. This Article IX and the agreements of the
Company, Parent and Merger Sub contained in Articles I, II, III and IV and
Sections 6.7 (Taxation and Accounting), 6.12 (Benefits), 6.13 (Expenses), 6.14
and (Indemnification; Directors' and Officers' Insurance) shall survive the
consummation of the Merger. This Article IX and the agreements of the Company,
Parent and Merger Sub contained in Section 6.13 (Expenses), Section 6.17
(Funding Mechanism) and Section 8.5 (Effect of Termination and Abandonment)
shall survive the termination of this Agreement. All other representations,
warranties, agreements and covenants in this Agreement shall not survive the
consummation of the Merger or the termination of this Agreement.
9.2. Modification or Amendment. Subject to the provisions of
applicable law, at any time prior to the Effective Time, the parties hereto may
modify or amend this Agreement, by written agreement executed and delivered by
duly authorized officers of the respective parties.
9.3. Waiver of Conditions. The conditions to each of the
parties' obligations to consummate the Merger are for the sole benefit of such
party and may be waived by such party in whole or in part to the extent
permitted by applicable law.
9.4. Counterparts. This Agreement may be executed in any
number of counterparts, each such counterpart being deemed to be an original
instrument, and all such counterparts shall together constitute the same
agreement.
9.5. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL. (a) THIS
AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE
INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAWS OF THE
STATE OF NEW YORK WITHOUT REGARD TO THE CONFLICT OF LAW PRINCIPLES THEREOF. The
parties hereby irrevocably submit to the
-69-
<PAGE>
jurisdiction of the courts of the State of New York and the Federal courts of
the United States of America located in the Borough of Manhattan, The City of
New York solely in respect of the interpretation and enforcement of the
provisions of this Agreement, the Stock Option Agreement and the Voting
Agreement and of the documents referred to in this Agreement, the Stock Option
Agreement and the Voting Agreement, and in respect of the transactions
contemplated hereby and thereby, and hereby waive, and agree not to assert, as a
defense in any action, suit or proceeding for the interpretation or enforcement
hereof or of any such document, that it is not subject thereto or that such
action, suit or proceeding may not be brought or is not maintainable in said
courts or that the venue thereof may not be appropriate or that this Agreement,
the Stock Option Agreement or the Voting Agreement or any such document may not
be enforced in or by such courts, and the parties hereto irrevocably agree that
all claims with respect to such action or proceeding shall be heard and
determined in such a New York State or Federal court. The parties hereby consent
to and grant any such court jurisdiction over the person of such parties and
over the subject matter of such dispute and agree that mailing of process or
other papers in connection with any such action or proceeding in the manner
provided in Section 9.6 or in such other manner as may be permitted by law,
shall be valid and sufficient service thereof.
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY
WHICH MAY ARISE UNDER THIS AGREEMENT, THE STOCK OPTION AGREEMENT OR THE VOTING
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE
EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH
PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE STOCK OPTION
AGREEMENT OR THE VOTING AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR
THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER, (II) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH PARTY MAKES THIS WAIVER
VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT OR THE STOCK OPTION AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.5.
-70-
<PAGE>
9.6. Notices. Any notice, request, instruction or other
document to be given hereunder by any party to the others shall be in writing
and delivered personally or sent by registered or certified mail, postage
prepaid, or by facsimile:
if to Parent or Merger Sub
Richard T. Collier
Pharmacia & Upjohn, Inc.
95 Corporate Drive
Bridgewater, New Jersey 08807
fax: (908) 306-4489
with copies to:
Neil T. Anderson
Matthew G. Hurd
Martin J. Travers
Sullivan & Cromwell
125 Broad Street
New York, NY 10004
fax: (212) 558-3588
if to the Company
Bruce E. MacMillan
SUGEN, Inc.
230 East Grand Avenue
South San Francisco, CA 94080
fax: (650) 553-8342
with copies to:
Alan C. Mendelson
Suzanne Sawochka Hooper
Gianna M. Bosko
Cooley Godward LLP
5 Palo Alto Square
3000 El Camino Real
Palo Alto, California 94306
fax: (650) 857-0663
or to such other persons or addresses as may be designated in writing by the
party to receive such notice as provided above.
-71-
<PAGE>
9.7. Entire Agreement. This Agreement (including any exhibits
and schedules hereto), the Stock Option Agreement, the Company Confidentiality
Agreement and the Parent Confidentiality Agreement constitute the entire
agreement, and supersede all other prior agreements, understandings,
representations and warranties both written and oral, among the parties, with
respect to the subject matter hereof.
9.8. No Third Party Beneficiaries. Except as provided in
Section 6.14 (Indemnification; Directors' and Officers' Insurance), this
Agreement is not intended to confer upon any Person other than the parties
hereto any rights or remedies hereunder.
9.9. Obligations of Parent and of the Company. Whenever this
Agreement requires a Subsidiary of Parent to take any action, such requirement
shall be deemed to include an undertaking on the part of Parent to cause such
Subsidiary to take such action. Whenever this Agreement requires a Subsidiary of
the Company to take any action, such requirement shall be deemed to include an
undertaking on the part of the Company to cause such Subsidiary to take such
action and, after the Effective Time, on the part of the Surviving Corporation
to cause such Subsidiary to take such action.
9.10. Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall
not affect the validity or enforceability of the other provisions hereof. If any
provision of this Agreement, or the application thereof to any Person or any
circumstance, is invalid or unenforceable, (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application
thereof, in any other jurisdiction.
9.11. Specific Performance. The parties hereto each
acknowledge that, in view of the uniqueness of the subject matter hereof, the
parties hereto would not have an adequate remedy at law for money damages if
this Agreement
-72-
<PAGE>
were not performed in accordance with its terms, and therefore agree that the
parties hereto shall be entitled to specific enforcement of the terms hereof in
addition to any other remedy to which the parties hereto may be entitled at law
or in equity.
9.12. Interpretation. The table of contents and headings
herein are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the
provisions hereof. Where a reference in this Agreement is made to a Section,
Schedule or Exhibit, such reference shall be to a Section of or Schedule or
Exhibit to this Agreement unless otherwise indicated. Whenever the words
"include," "includes" or "including" are used in this Agreement, they shall be
deemed to be followed by the words "without limitation."
9.13. Assignment. This Agreement shall not be assignable by
operation of law or otherwise; provided, however, that Parent may designate, by
written notice to the Company, another wholly owned direct subsidiary to be a
Constituent Corporation in lieu of Merger Sub, in the event of which, all
references herein to Merger Sub shall be deemed references to such other
subsidiary except that all representations and warranties made herein with
respect to Merger Sub as of the date of this Agreement shall be deemed
representations and warranties made with respect to such other subsidiary as of
the date of such designation. Any purported assignment made in contravention of
this Agreement shall be null and void.
9.14. Captions. The Article, Section and paragraph captions
herein are for convenience of reference only and do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the
provisions hereof.
-73-
<PAGE>
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by duly authorized officers of the parties hereto as of the date
hereof.
SUGEN, INC.
By: /s/ Stephen Evans-Freke
---------------------------------
Name: Stephen Evans-Freke
Title: Chairman of the Board and
Chief Executive Officer
PHARMACIA & UPJOHN, INC.
By: /s/ Christopher J. Coughlin
---------------------------------
Name: Christopher J. Coughlin
Title: Executive Vice President
UNIVERSITY ACQUISITION CORP.
By: /s/ Mats Petterson
---------------------------------
Name: Mats Petterson
Title: Senior Vice President
<PAGE>
EXHIBIT AZ-1
(AstraZeneca Affiliates Letter)
TO PHARMACIA & UPJOHN:
Re: Agreement and Plan of Merger
Ladies and Gentlemen:
The undersigned has been advised that the undersigned may be
considered an "affiliate" of SUGEN, Inc. (the "Company") for purposes of (i)
Rule 145 of the General Rules and Regulations (the "Rules and Regulations") of
the Securities and Exchange Commission (the "SEC") under the Securities Act of
1933, as amended (the "Securities Act"), and/or (ii) SEC Accounting Series
Releases 130 and 135, as amended. Pursuant to the Agreement and Plan of Merger,
dated as of June 15, 1999 (the "Merger Agreement"), among the Company, Pharmacia
& Upjohn, Inc. ("Parent") and University Acquisition Corp. ("Merger Sub"), the
undersigned may receive shares of common stock of Parent (the "Shares") in
exchange for the shares of stock of the Company owned by the undersigned at the
effective date of the merger provided for in the Merger Agreement (the
"Merger").
The undersigned represents and warrants to, and agrees with,
Parent that:
A. The undersigned will not make any sale, transfer or other
disposition of the undersigned's Shares in violation of the Securities
Act or the Rules and Regulations.
B. The undersigned has been advised that the offering, sale
and delivery of the Shares to the undersigned in the Merger will be
registered under the Securities Act on a Registration Statement on Form
S-4. The undersigned has also been advised, however, that, since the
undersigned may be considered an "affiliate" of the Company at the time
the Merger Agreement is submitted for a vote of the stockholders of the
Company, any public offering or sale by the undersigned of any of the
Shares will, under current law, require either (i) the further
registration under the Securities Act of the Shares to be offered and
sold, (ii) compliance by the undersigned with SEC Rule 145 under the
Securities Act in connection with such offer and sale or (iii) the
availability of another exemption
AZ-1-1
<PAGE>
from registration of such Shares under the Securities Act for such
offer and sale.
C. The undersigned has carefully read this letter agreement
and the Merger Agreement and has discussed their requirements and other
applicable limitations upon the undersigned's ability to sell, transfer
or otherwise dispose of the Shares, to the extent the undersigned felt
necessary, with the undersigned's counsel or counsel for the Company.
D. The undersigned has been informed by the Company that the
Shares have not been registered under the Securities Act for
distribution by the undersigned and that the Shares must be held by the
undersigned for at least two years unless (i) such Shares have been
registered for distribution under the Securities Act, (ii) a sale of
the Shares is made in conformity with the volume and other limitations
of SEC Rule 145 under the Securities Act or (iii) in the opinion of
counsel reasonably acceptable to Parent, some other exemption from
registration under the Securities Act is available with respect to any
such proposed sale, transfer or other disposition of the Shares.
E. The undersigned understands that Parent is under no
obligation to register the sale, transfer or other disposition of the
Shares by the undersigned or on behalf of the undersigned under the
Securities Act or to take any other action necessary in order to make
compliance with an exemption from such registration available to the
undersigned.
F. The undersigned also understands that stop transfer
instructions will be given to all transfer agents for the Shares and
that there will be placed on the certificates for the Shares issued to
the undersigned, or any replacements or substitutes therefor, a legend
stating in substance:
"The shares represented by this certificate were
issued in a transaction to which Rule 145 under the Securities
Act of 1933 applies. The shares represented by this
certificate may only be transferred in accordance with the
terms of an agreement, dated June 15, 1999, between the
registered
AZ-1-2
<PAGE>
holder hereof and the issuer, a copy of which agreement will
be mailed to the holder hereof without charge promptly after
receipt by the issuer of a written request therefor."
G. The undersigned also understands that, unless the transfer
of the undersigned's Shares has been registered under the Securities
Act or the undersigned represents and warrants to Parent that any such
transfer has been made in conformity with the provisions of SEC Rule
145, Parent shall have the right to place the following legend on the
certificates issued to any transferee of such Shares:
"The shares represented by this certificate have
not been registered under the Securities Act of 1933 and were
acquired from a person who received such shares in a
transaction to which Rule 145 under the Securities Act of 1933
applies. The shares may not be sold, pledged or otherwise
transferred except in accordance with an exemption from the
registration requirements of the Securities Act of 1933."
It is understood and agreed that the legends set forth in
paragraphs F and G above shall be removed by the delivery of substitute
certificates without such legend if the undersigned shall have delivered to
Parent a copy of a letter from the staff of the SEC, or an opinion of counsel in
form and substance reasonably satisfactory to Parent, to the effect that such
legend is not required for purposes of the Securities Act. In addition, the
legend referred to in paragraph F above will be removed upon written request at
any time more than two years after the effective date of the Merger.
The undersigned further represents to and covenants with
Parent that the undersigned will not, within the 30 days prior to the Closing
Date (as defined in the Merger Agreement), sell, transfer or otherwise dispose
of any shares of stock of the Company except pursuant to and upon consummation
of the Merger, and that the undersigned will not sell, transfer or otherwise
dispose of any Shares (whether or not acquired by the undersigned in the Merger)
until after such time as results covering at least 30 days of combined
operations of the Company and Parent have been
AZ-1-3
<PAGE>
published by Parent, in the form of a quarterly earnings press release, an
effective registration statement filed with the SEC, a report filed with the SEC
on Form 10-K, 10-Q or 8-K or any other public filing or announcement that
includes such combined results of operations. Furthermore, the undersigned
understands that the Company and Parent will give stop transfer instructions to
their respective transfer agents in order to prevent the breach of the covenants
made by the undersigned in this paragraph.
Execution of this letter should not be considered an admission
on the part of the undersigned that it is an "affiliate" of the Company, nor a
waiver of any rights that the undersigned may have to object at any time
following the date hereof to any claim that the undersigned is an "affiliate" of
the Company.
This letter and that certain Voting Agreement between the
undersigned and Parent constitutes the complete understanding between Parent and
the undersigned concerning the subject matter hereof. The surviving corporation
is expressly intended to be a beneficiary of this letter agreement. Any notice
required to be sent to any party hereunder shall be sent by registered or
certified mail, return receipt requested, using the addresses set forth herein
or such other address as shall be furnished in writing by the parties. This
letter shall be governed by, and construed and interpreted in accordance with,
the laws of the State of New York applicable to contracts made and to be
performed within such state.
Very truly yours,
ZENECA LIMITED
_____________________________________
ACCEPTED:
PHARMACIA & UPJOHN, INC.
By: _____________________________
AZ-1-4
<PAGE>
EXHIBIT A-1
(Company Affiliates Letter)
TO PHARMACIA & UPJOHN, INC.:
Re: Agreement and Plan of Merger
Ladies and Gentlemen:
The undersigned has been advised that the undersigned may be
considered an "affiliate" of SUGEN, Inc. (the "Company") for purposes of (i)
Rule 145 of the General Rules and Regulations (the "Rules and Regulations") of
the Securities and Exchange Commission (the "SEC") under the Securities Act of
1933, as amended (the "Securities Act"), and/or (ii) SEC Accounting Series
Releases 130 and 135, as amended. Pursuant to the Agreement and Plan of Merger,
dated as of June 15, 1999 (the "Merger Agreement"), among the Company, Pharmacia
& Upjohn, Inc. ("Parent") and University Acquisition Corp. ("Merger Sub"), the
undersigned may receive shares of common stock of Parent (the "Shares") in
exchange for the shares of stock of the Company owned by the undersigned at the
effective date of the merger provided for in the Merger Agreement (the
"Merger").
The undersigned represents and warrants to, and agrees with,
Parent that:
A. The undersigned will not make any sale, transfer or other
disposition of the undersigned's Shares in violation of the Securities
Act or the Rules and Regulations.
B. The undersigned has been advised that the offering, sale
and delivery of the Shares to the undersigned in the Merger will be
registered under the Securities Act on a Registration Statement on Form
S-4. The undersigned has also been advised, however, that, since the
undersigned may be considered an "affiliate" of the Company at the time
the Merger Agreement is submitted for a vote of the stockholders of the
Company, any public offering or sale by the undersigned of any of the
Shares will, under current law, require either (i) the further
registration under the Securities Act of the Shares to be offered and
sold, (ii) compliance by the undersigned with SEC Rule 145 under the
Securities Act in connection with such offer and sale or (iii) the
availability of another exemption
A-1-1
<PAGE>
from registration of such Shares under the Securities Act for such
offer and sale.
C. The undersigned has carefully read this letter agreement
and the Merger Agreement and has discussed their requirements and other
applicable limitations upon the undersigned's ability to sell, transfer
or otherwise dispose of the Shares, to the extent the undersigned felt
necessary, with the undersigned's counsel or counsel for the Company.
D. The undersigned has been informed by the Company that the
Shares have not been registered under the Securities Act for
distribution by the undersigned and that the Shares must be held by the
undersigned for at least two years unless (i) such Shares have been
registered for distribution under the Securities Act, (ii) a sale of
the Shares is made in conformity with the volume and other limitations
of SEC Rule 145 under the Securities Act or (iii) in the opinion of
counsel reasonably acceptable to Parent, some other exemption from
registration under the Securities Act is available with respect to any
such proposed sale, transfer or other disposition of the Shares.
E. The undersigned understands that Parent is under no
obligation to register the sale, transfer or other disposition of the
Shares by the undersigned or on behalf of the undersigned under the
Securities Act or to take any other action necessary in order to make
compliance with an exemption from such registration available to the
undersigned.
F. The undersigned also understands that stop transfer
instructions will be given to all transfer agents for the Shares and
that there will be placed on the certificates for the Shares issued to
the undersigned, or any replacements or substitutes therefor, a legend
stating in substance:
"The shares represented by this certificate were
issued in a transaction to which Rule 145 under the Securities
Act of 1933 applies. The shares represented by this
certificate may only be transferred in accordance with the
terms of an agreement, dated June 15, 1999, between the
registered
A-1-2
<PAGE>
holder hereof and the issuer, a copy of which agreement will
be mailed to the holder hereof without charge promptly after
receipt by the issuer of a written request therefor."
G. The undersigned also understands that, unless the transfer
of the undersigned's Shares has been registered under the Securities
Act or the undersigned represents and warrants to Parent that any such
transfer has been made in conformity with the provisions of SEC Rule
145, Parent shall have the right to place the following legend on the
certificates issued to any transferee of such Shares:
"The shares represented by this certificate have
not been registered under the Securities Act of 1933 and were
acquired from a person who received such shares in a
transaction to which Rule 145 under the Securities Act of 1933
applies. The shares may not be sold, pledged or otherwise
transferred except in accordance with an exemption from the
registration requirements of the Securities Act of 1933."
It is understood and agreed that the legends set forth in
paragraphs F and G above shall be removed by the delivery of substitute
certificates without such legend if the undersigned shall have delivered to
Parent a copy of a letter from the staff of the SEC, or an opinion of counsel in
form and substance reasonably satisfactory to Parent, to the effect that such
legend is not required for purposes of the Securities Act. In addition, the
legend referred to in Paragraph F above will be removed upon written request at
any time more than two years after the effective date of the Merger.
The undersigned further represents to and covenants with
Parent that the undersigned will not, within the 30 days prior to the Closing
Date (as defined in the Merger Agreement), sell, transfer or otherwise dispose
of any shares of stock of the Company except pursuant to and upon consummation
of the Merger, and that the undersigned will not sell, transfer or otherwise
dispose of any Shares (whether or not acquired by the undersigned in the Merger)
until after such time as results covering at least 30 days of combined
operations of the Company and Parent have been
A-1-3
<PAGE>
published by Parent, in the form of a quarterly earnings press release, an
effective registration statement filed with the SEC, a report filed with the SEC
on Form 10-K, 10-Q or 8-K or any other public filing or announcement that
includes such combined results of operations. Furthermore, the undersigned
understands that the Company and Parent will give stop transfer instructions to
their respective transfer agents in order to prevent the breach of the covenants
made by the undersigned in this paragraph.
Execution of this letter should not be considered an admission
on the part of the undersigned that it is an "affiliate" of the Company, nor a
waiver of any rights that the undersigned may have to object at any time
following the date hereof to any claim that the undersigned is an "affiliate" of
the Company.
This letter constitutes the complete understanding between
Parent and the undersigned concerning the subject matter hereof. The surviving
corporation is expressly intended to be a beneficiary of this letter agreement.
Any notice required to be sent to any party hereunder shall be sent by
registered or certified mail, return receipt requested, using the addresses set
forth herein or such other address as shall be furnished in writing by the
parties. This letter shall be governed by, and construed and interpreted in
accordance with, the laws of the State of New York applicable to contracts made
and to be performed within such state.
Very truly yours,
_________________________________
(Name of Affiliate)
ACCEPTED:
PHARMACIA & UPJOHN, INC.
By: _________________________________
A-1-4
<PAGE>
ANNEX B-1
TO PHARMACIA & UPJOHN, INC.:
Ladies and Gentlemen:
I have been advised that as of the date hereof, I may be
deemed to be an "affiliate" of Pharmacia & Upjohn, Inc., a Delaware corporation
("Parent"), as such term (i) is defined for purposes of paragraphs (c) and (d)
of Rule 145 of the Rules and Regulations of the Securities and Exchange
Commission (the "Commission") under the Securities Act of 1933, as amended, or
(ii) is used in and for purposes of Accounting Series Releases 130 and 135, as
amended, of the Commission. Pursuant to the terms of the Agreement and Plan of
Merger (the "Merger Agreement"), dated as of June 15, 1999, as it may be
amended, supplemented or modified from time to time, among SUGEN, a Delaware
corporation (the "Company"), Parent, and University Acquisition Corp., a
Delaware corporation to be formed as a wholly owned subsidiary of Parent
("Merger Sub"), Merger Sub will be merged with and into the Company (the
"Merger"). Capitalized terms used herein but not defined herein shall have the
meanings ascribed to such terms in the Merger Agreement.
I further understand that the Merger will be treated for
financial accounting purposes as a "pooling of interests" in accordance with
generally accepted accounting principles and that the Staff of the Commission
has issued certain guidelines that should be followed to ensure the pooling of
the entities.
In consideration of the agreements contained herein, the
Company's reliance on this letter in connection with the consummation of the
Merger and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, I hereby represent, warrant and
agree that I will not make any sale, transfer, or other disposition of any
shares of Common Stock, par value $0.01 per share of Parent during the period
beginning 30 days prior to the Closing Date (as defined in the Merger Agreement)
and ending after such time as results covering at least 30 days of combined
operations of the Company and Parent have been published by Parent, in the form
of a quarterly earnings report, an effective registration
B-1-1
<PAGE>
ANNEX B-1
statement filed with the Commission, a report to the Commission on Form 10-K,
10-Q or 8-K, or any other public filing or announcement which includes such
combined results of operations.
Execution of this letter should not be considered an admission
on my part that I am an "affiliate" of Parent as described in the first
paragraph of this letter, or as a waiver of any rights I may have to object to
any claim that I am such an affiliate on or after the date of this letter.
This letter agreement constitutes the complete understanding
between the Company and me concerning the subject matter hereof. Any notice
required to be sent to either party hereunder shall be sent by registered or
certified mail, return receipt requested, using the addresses set forth herein
or such other address as shall be furnished in writing by the parties. This
letter agreement shall be governed by and construed and interpreted in
accordance with, the laws of the State of New York.
If you are in agreement with the foregoing, please so indicate
by signing below and returning a copy of this letter to the undersigned, at
which time this letter shall become a binding agreement between us.
Very truly yours,
_______________________________
Name:
Address:
Accepted this ____ day of ___________, 1999.
PHARMACIA & UPJOHN, INC.
By:______________________
Name:
Title:
B-1-2
EXHIBIT 2.2
EXECUTION COPY
STOCK OPTION AGREEMENT
STOCK OPTION AGREEMENT, dated as of June 15, 1999 (the
"Agreement"), between Pharmacia & Upjohn, Inc., a Delaware corporation (the
"Grantee"), and SUGEN, Inc., a Delaware corporation (the "Grantor").
WHEREAS, the Grantee, University Acquisition Corp., a Delaware
corporation and a wholly owned subsidiary of the Grantee ("Merger Sub"), and the
Grantor are entering into an Agreement and Plan of Merger, dated as of the date
hereof (the "Merger Agreement"), which provides, among other things, for the
merger of Merger Sub with and into Grantor (the "Merger");
WHEREAS, the Grantee and Merger Sub have requested that the
Grantor grant to the Grantee an option to purchase up to 3,372,255 shares of
Common Stock, par value $0.01 per share, of the Grantor (the "Common Stock"), on
the terms and subject to the conditions hereof; and
WHEREAS, the Grantor is willing to grant the Grantee the
requested option.
NOW, THEREFORE, in consideration of the premises and the
mutual covenants and agreements set forth herein, the parties hereto agree as
follows:
1. The Option; Exercise; Adjustments; Payment of Spread;
Repurchase Right. (a) Contemporaneously herewith the Grantee, Merger Sub and the
Grantor are entering into the Merger Agreement. Subject to the other terms and
conditions set forth herein, the Grantor hereby grants to the Grantee an
irrevocable option (the "Option") to purchase up to 3,372,255 shares of Common
Stock (the "Shares") at a cash purchase price equal to $31.00 per share (the
"Purchase Price"). The Option may be exercised by the Grantee, in whole or in
part, at any time, or from time to time, following (but not prior to) the
occurrence of the events set forth in any of clauses (i), (ii), (iii) or (iv) of
Section 2(d) hereof, and prior to the Termination Date (as defined herein).
(b) In the event the Grantee wishes to exercise the Option,
the Grantee shall send a written notice to the Grantor (the "Stock Exercise
Notice") specifying the total number of Shares it wishes to purchase and a date
(subject
<PAGE>
to the expiration or termination of any applicable waiting period under the HSR
Act (as defined below)) not later than 10 business days and not earlier than
three business days following the date such notice is given for the closing of
such purchase. In the event of any change in the number of issued and
outstanding shares of capital stock of the Company (by reason of any stock
dividend, stock split, split-up, recapitalization, merger, issuance of capital
stock upon exercise of warrants or options or any other event), the number of
Shares subject to this Option and the purchase price per Share shall be
appropriately adjusted to restore the Grantee to its rights hereunder, including
its right to purchase Shares representing 19.9% of the capital stock of the
Grantor entitled to vote generally for the election of the directors of the
Grantor which is issued and outstanding immediately prior to the exercise of the
Option.
(c) If at any time the Option is then exercisable pursuant to
the terms of Section 1(a) hereof and at or prior to such time the termination
fee referred to in Section 8.5(b) of the Merger Agreement shall have become
payable, the Grantee may from time to time elect, in lieu of exercising the
Option to purchase Shares provided in Section 1(a) hereof, to send a written
notice to the Grantor (a "Cash Exercise Notice") specifying a date not later
than 20 business days and not earlier than 10 business days following the date
such notice is given on which date the Grantor shall pay to the Grantee an
amount in cash (the "Cancellation Amount") equal to the Spread (as hereinafter
defined) multiplied by all or such portion of the Shares subject to the Option
as Grantee shall specify. As used herein "Spread" shall mean the excess, if any,
over the Purchase Price of the higher of (x) if applicable, the highest price
per share of Common Stock (including any brokerage commissions, transfer taxes
and soliciting dealers' fees) paid or proposed to be paid by any person pursuant
to any Acquisition Proposal (as defined in the Merger Agreement) occurring after
the date of this Agreement and prior to the Termination Date (the "Alternative
Purchase Price") or (y) the average of the closing bid and asked prices of the
Common Stock on the Nasdaq National Market ("Nasdaq") or on such other national
securities on which the shares of the Grantor's common stock are then listed on
the last trading day immediately prior to the date of the Cash Exercise Notice
(the "Closing Price"). If the Alternative Purchase Price includes any property
other than cash, the Alternative Purchase Price shall be the sum of (i) the
fixed cash
-2-
<PAGE>
amount, if any, included in the Alternative Purchase Price plus (ii) the fair
market value of such other property. If such other property consists of
securities with an existing public trading market, the average of the closing
prices (or the average of the closing bid and asked prices if closing prices are
unavailable) for such securities in their principal public trading market on the
five trading days ending five days prior to the date of the Cash Exercise Notice
shall be deemed to equal the fair market value of such property. If such other
property consists of something other than cash or securities with an existing
public trading market and, as of the payment date for the Spread, agreement on
the value of such other property has not been reached, the Alternative Purchase
Price shall be deemed to equal the Closing Price. Upon exercise of its right to
receive cash pursuant to this Section 1(c), the obligations of the Grantor to
deliver Shares pursuant to Section 3 shall be terminated with respect to such
number of Shares for which the Grantee shall have elected to be paid the Spread.
(d) At the request of the Grantor at any time during the
180-day period commencing on each date on which the Option is exercised (the
"Call Period"), the Grantor may repurchase from the Grantee, and the Grantee
shall sell to the Grantor, any or all of the Shares acquired by the Grantee
pursuant hereto as a result of such exercise and with respect to which the
Grantee has beneficial ownership at the time of such repurchase at a price per
share equal to the Repurchase Price (defined below) per share in respect of the
Shares so acquired (such price per share multiplied by the number of Shares to
be repurchased pursuant to this Section 1(d) being herein called the "Repurchase
Consideration"). Each date on which the Grantor exercises its rights under this
Section 1(d) by delivering its request to the Grantee is referred to as a
"Grantor Request Date." "Repurchase Price" per share shall be the greater of (i)
the Purchase Price, and (ii) the average (rounded to the nearest cent, or if
there shall not be a nearest cent, to the next highest cent) of the volume
weighted averages (rounded to the nearest cent, or if there shall not be a
nearest cent, to the next highest cent) of the closing ask prices of one share
of Common Stock on Nasdaq as reported by Bloomberg Financial Markets (or such
other source as the parties shall agree in writing) for each of the Trading
Days. "Trading Days" means the Nasdaq trading days during the Call Period and
prior to the applicable Grantor Request Date. If the Grantor exercises its
rights under this Section 1(d), the
-3-
<PAGE>
Grantor shall, within five business days after the applicable Grantor Request
Date, pay the applicable Repurchase Consideration in immediately available
funds, and the Grantee shall surrender to the Grantor certificates evidencing
the Shares purchased hereunder, and the Grantee shall warrant to the Grantor
that, immediately prior to the repurchase thereof pursuant to this Section 1(d),
the Grantee had sole record and beneficial ownership of such Shares and that
such Shares were then held free and clear of all encumbrances.
2. Conditions to Delivery of Shares. The Grantor's obligation
to deliver Shares upon exercise of the Option is subject only to the conditions
that:
(a) No preliminary or permanent injunction or other order
issued by any federal or state court of competent jurisdiction
prohibiting the delivery of the Shares shall be in effect; and
(b) Any applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 (the "HSR Act") shall have expired
or been terminated; and
(c) the representations and warranties of the Grantee made in
Section 5 of this Agreement shall be true and correct in all material
respects as of the date of the closing of the issuance of the Shares;
and
(d) (i) in the event that (A) a bona fide Acquisition Proposal
(as defined in the Merger Agreement) shall have been made to the
Company or any of its subsidiaries or any of its stockholders or any
person or entity shall have announced an intention (whether or not
conditional) to make an Acquisition Proposal with respect to the
Company or any of its subsidiaries, and on or following the date of the
Merger Agreement but prior to the date of the Stockholders Meeting (as
defined in the Merger Agreement) such Acquisition Proposal,
announcement or intention is or becomes publicly known, and (B) on or
following the date of the Merger Agreement but prior to the time such
Acquisition Proposal, announcement or intention is or becomes publicly
known, the occurrence of a
-4-
<PAGE>
Parent Material Adverse Effect (as defined in the Merger Agreement)
shall not have become publicly known, and (C) on or following the date
on which such Acquisition Proposal, announcement or intention is or
becomes publicly known, the Merger Agreement is terminated by either
the Grantee or the Grantor pursuant to Section 8.2(ii) of the Merger
Agreement, or (ii) the Merger Agreement is terminated by the Grantor
pursuant to Section 8.3(a) of the Merger Agreement; or (iii) the
Merger Agreement is terminated by the Grantee pursuant to Section
8.4(a) of the Merger Agreement; or (iv) the Grantor shall have
delivered to Grantee the written notification pursuant to Section
8.3(a)(ii) of the Merger Agreement and the Grantee shall have notified
the Grantor in writing that the Grantee does not intend to match the
Superior Proposal (as defined in the Merger Agreement) referred to in
such notification. As used in this Agreement, "person" shall have the
meaning specified in Sections 3(a)(9) and 13(d)(3) of the Exchange Act.
3. The Closing. (a) Any closing hereunder shall take place on
the date specified by the Grantee in its Stock Exercise Notice or Cash Exercise
Notice or as specified in Section 1(d), as the case may be, at 10:00 A.M., local
time, at the offices of Sullivan & Cromwell, 125 Broad Street, New York, New
York, or, if the conditions set forth in Section 2(a), (b) or (c) have not then
been satisfied, on the second business day following the satisfaction of such
conditions, or at such other time and place as the parties hereto may agree (the
"Closing Date"). On the Closing Date, (i) in the event of a closing pursuant to
Section 1(b) hereof, the Grantor will deliver to the Grantee a certificate or
certificates, representing the Shares in the denominations designated by the
Grantee in its Stock Exercise Notice and the Grantee will purchase such Shares
from the Grantor at the price per Share equal to the Purchase Price, (ii) in the
event of a closing pursuant to Section 1(c) hereof, the Grantor will deliver to
the Grantee cash in an amount determined pursuant to Section 1(c) hereof; or
(iii) in the event of a closing pursuant to Section 1(d) hereof, the Grantor
will deliver to the Grantee cash in an amount determined pursuant to Section
1(d) hereof. Any payment made by the Grantee to the Grantor, or by the Grantor
to the Grantee, pursuant to this Agreement shall be made by
-5-
<PAGE>
certified or official bank check or by wire transfer of federal funds to a bank
designated by the party receiving such funds.
(b) The Grantee agrees not to transfer or otherwise dispose of
the Option or the Shares, or any interest therein, except in compliance with the
Securities Act of 1933, as amended (the "Securities Act") and any applicable
state securities law. The Grantee further agrees that the certificates
representing the Shares shall bear an appropriate legend relating to the fact
that such Shares have not been registered under the Securities Act.
4. Representations and Warranties of the Grantor. The Grantor
represents and warrants to the Grantee that (a) the Grantor is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware and has the requisite corporate power and authority to enter
into and perform this Agreement; (b) the execution and delivery of this
Agreement by the Grantor and the consummation by it of the transactions
contemplated hereby have been duly authorized by the Board of Directors of the
Grantor and this Agreement has been duly executed and delivered by a duly
authorized officer of the Grantor and constitutes a valid and binding obligation
of the Grantor, enforceable in accordance with its terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of
general applicability relating to or affecting creditors' rights and to general
equity principles; (c) the Grantor has taken all necessary corporate action to
authorize and reserve the Shares issuable upon exercise of the Option and the
Shares, when issued and delivered by the Grantor upon exercise of the Option and
paid for by the Grantee as contemplated hereby, will be duly authorized, validly
issued, fully paid and non-assessable and free of preemptive rights; (d) except
as otherwise required by the HSR Act or the rules and regulations of Nasdaq, the
execution and delivery of this Agreement by the Grantor and the consummation by
it of the transactions contemplated hereby do not require the consent, waiver,
approval or authorization of or any filing with any person or public authority
and will not violate, result in a breach of or the acceleration of any
obligation under, or constitute a default under, any provision of the Grantor's
certificate of incorporation or bylaws, or any indenture, mortgage, lien, lease,
agreement, contract, instrument, order, rule, regulation, judgment, ordinance,
or decree, or
-6-
<PAGE>
restriction by which the Grantor or any of its subsidiaries or any of their
respective properties or assets is bound; (e) no "fair price", "moratorium",
"control share acquisition," "interested shareholder" or other form of
antitakeover statute or regulation (including but not limited to Section 203 of
the Delaware General Corporation Law) is or shall be applicable to the
acquisition of Shares pursuant to this Agreement; and (f) the Grantor has taken
all corporate action necessary so that any Shares acquired pursuant to this
Agreement shall not be counted for purposes of determining the number of shares
of Common Stock beneficially owned by the Grantee or any of its Affiliates or
Associates pursuant to the Rights Agreement (as defined in the Merger Agreement,
the terms "Affiliate" and "Associate" having the respective meanings ascribed to
them in the Rights Agreement).
5. Representations and Warranties of the Grantee. The Grantee
represents and warrants to the Grantor that (a) the Grantee is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware and has the requisite corporate power and authority to enter
into and perform this Agreement, (b) the execution and delivery of this
Agreement by the Grantee and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action
on the part of the Grantee and this Agreement has been duly executed and
delivered by a duly authorized officer of the Grantee and constitutes a valid
and binding obligation of the Grantee, enforceable in accordance with its terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditors' rights and to general equity principles; and (c) the Grantee is
acquiring the Option and, if and when it exercises the Option, will be acquiring
the Shares issuable upon the exercise thereof for its own account and not with a
view to distribution or resale in any manner which would be in violation of the
Securities Act.
6. Listing of Shares; Filings; Governmental Consents. Subject
to applicable law and the rules and regulations of Nasdaq or such other national
securities exchange on which the shares of the Grantor's common stock are then
listed, after the Option becomes exercisable hereunder, the Grantor will
promptly file an application to list the Shares on Nasdaq or on such other
national securi-
-7-
<PAGE>
ties exchange on which the shares of the Grantor's common stock are then listed
and will use its reasonable best efforts to obtain approval of such listing and
to effect all necessary filings by the Grantor under the HSR Act; provided,
however, that if the Grantor is unable to effect such listing on Nasdaq by the
Closing Date, the Grantor will nevertheless be obligated to deliver the Shares
upon the Closing Date. Each of the parties hereto will use its reasonable best
efforts to obtain consents of all third parties and governmental authorities, if
any, necessary to the consummation of the transactions contemplated by this
Agreement.
7. Registration Rights. (a) In the event that the Grantee
shall desire to sell any of the Shares within two years after the purchase of
such Shares pursuant to this Agreement, and such sale requires, in the opinion
of counsel to the Grantee, which opinion shall be reasonably satisfactory to the
Grantor and its counsel, registration of such Shares under the Securities Act,
the Grantor will cooperate with the Grantee and any underwriters (which
underwriters must be reasonably satisfactory to the Grantor) in registering such
Shares for resale, including, without limitation, promptly filing a registration
statement which complies with the requirements of applicable federal and state
securities laws, and entering into an underwriting agreement with such
underwriters upon such terms and conditions as are customarily contained in
underwriting agreements with respect to secondary distributions; provided that
the Grantor shall not be required to have declared effective more than two
registration statements hereunder and shall be entitled to delay the filing or
effectiveness of any registration statement and may suspend the use of any
registration statement (and related prospectus) for one or more periods of time
not exceeding an aggregate of 60 days in any one year period if the offering
would, in the judgment of the board of directors of the Grantor, require
premature disclosure of any material corporate development or material
transaction involving the Grantor or interfere with any previously planned
securities offering by the Grantor. In addition, upon receipt of notice of the
happening of any event as a result of which any registration statement,
prospectus or prospectus supplement, contains any untrue statements of material
fact or fails or omits to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under
which they are made, not misleading the Grantee shall
-8-
<PAGE>
forthwith discontinue the disposition of any Shares under such registration
statement, prospectus or prospectus supplement until the Grantee receives from
the Grantor copies (which subject to the limitations on suspension set forth
above shall promptly be made available by the Grantor) of an amended or
supplemented registration statement, prospectus or supplement so that, as
thereafter delivered to purchasers of such Shares, such registration statement,
prospectus or prospectus supplement shall not contain any untrue statement of
material fact or fail or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they are made, not misleading.
(b) If the Common Stock is registered pursuant to the
provisions of this Section 7, the Grantor agrees (i) to furnish copies of the
registration statement and the prospectus relating to the Shares covered thereby
in such numbers as the Grantee may from time to time reasonably request and (ii)
if any event shall occur as a result of which it becomes necessary to amend or
supplement any registration statement or prospectus, to prepare and file under
the applicable securities laws such amendments and supplements as may be
necessary to keep available for at least 45 days a prospectus covering the
Shares meeting the requirements of such securities laws, and to furnish the
Grantee such numbers of copies of the registration statement and prospectus as
amended or supplemented as may reasonably be requested. The Grantor shall bear
the cost of the registration, including, but not limited to, all registration
and filing fees, printing expenses, and fees and disbursements of counsel and
accountants for the Grantor, except that the Grantee shall pay the fees and
disbursements of its counsel, and the underwriting fees and selling commissions
applicable to the shares of Common Stock sold by the Grantee. The Grantor shall
indemnify and hold harmless (i) the Grantee, its affiliates and its officers and
directors and (ii) each underwriter and each person who controls any underwriter
within the meaning of the Securities Act or the Securities Exchange Act of 1934,
as amended (collectively, the "Underwriters") ((i) and (ii) being referred to as
"Indemnified Parties") against any losses, claims, damages, liabilities or
expenses, to which the Indemnified Parties may become subject, insofar as such
losses, claims, damages, liabilities (or actions in respect thereof) and
expenses arise out of or are based upon any untrue statement or alleged untrue
statement of any material
-9-
<PAGE>
fact contained or incorporated by reference in any registration statement filed
pursuant to this paragraph, or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading; provided, however,
that the Grantor will not be liable in any such case to the extent that any such
loss, liability, claim, damage or expense arises out of or is based upon (A) an
untrue statement or alleged untrue statement in or omission or alleged omission
from any such documents in reliance upon and in conformity with written
information furnished to the Grantor by the Indemnified Parties expressly for
use or incorporation by reference therein, or (B) the fact that the person
asserting any such loss, liability, claim, damage or expense did not receive a
copy of an amended preliminary prospectus or the final prospectus (or the final
prospectus as amended or supplemented) at or prior to the written confirmation
of the sale of the Shares to such person because of the failure of the Grantee
to so provide such amended preliminary or final prospectus.
(c) The Grantee and the Underwriters shall indemnify and hold
harmless the Grantor, its affiliates and its officers and directors against any
losses, claims, damages, liabilities or expenses to which the Grantor, its
affiliates and its officers and directors may become subject, insofar as such
losses, claims, damages, liabilities (or actions in respect thereof) and
expenses arise out of or are based upon (i) any untrue statement of any material
fact contained or incorporated by reference in any registration statement filed
pursuant to this paragraph, or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, in each case to the
extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with written information furnished to the Grantor by the Grantee or
the Underwriters, as applicable, specifically for use or incorporation by
reference therein, or (ii) the fact that the person asserting any such loss,
liability, claim, damage or expense did not receive a copy of an amended
preliminary prospectus or the final prospectus (or the final prospectus as
amended or supplemented) at or prior to the written confirmation of the sale of
the Shares to such person because of the failure of the
-10-
<PAGE>
Grantee to so provide such amended preliminary or final prospectus.
(d) Promptly after receipt by an indemnified party under
subsection (b) or (c) above of notice of the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made against the
indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; but the omission so to notify the
indemnifying party shall not relieve it from any liability which it may have to
any indemnified party otherwise than under such subsection. In case any such
action shall be brought against any indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate therein and, to the extent that it shall wish, jointly
with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel satisfactory to such indemnified party (who shall not,
except with the consent of the indemnified party, be counsel to the indemnifying
party), and, after notice from the indemnifying party to such indemnified party
of its election so to assume the defense thereof, the indemnifying party shall
not be liable to such indemnified party under such subsection for any legal
expenses of other counsel or any other expenses, in each case subsequently
incurred by such indemnified party, in connection with the defense thereof other
than reasonable costs of investigation. No indemnified party shall settle any
action or claim without the consent of the indemnifying party, which consent
shall not be unreasonably withheld or delayed.
8. Expenses. Each party hereto shall pay its own expenses
incurred in connection with this Agreement, except as otherwise specifically
provided herein.
9. Modification or Amendment. Subject to the provisions of
applicable law, the parties hereto may modify or amend this Agreement, by
written agreement executed and delivered by duly authorized officers of the
respective parties.
10. Counterparts. This Agreement may be executed in any number
of counterparts, each such counterpart being deemed to be an original
instrument, and all such counterparts shall together constitute the same
agreement.
-11-
<PAGE>
11. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL. (a) THIS
AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE
INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAWS OF THE
STATE OF NEW YORK WITHOUT REGARD TO THE CONFLICT OF LAW PRINCIPLES THEREOF. The
parties hereby irrevocably submit to the jurisdiction of the courts of the State
of New York and the Federal courts of the United States of America located in
the Borough of Manhattan, The City of New York solely in respect of the
interpretation and enforcement of the provisions of this Agreement, the Merger
Agreement and of the other documents referred to in this Agreement and the
Merger Agreement, and in respect of the transactions contemplated hereby and
thereby, and hereby waive, and agree not to assert, as a defense in any action,
suit or proceeding for the interpretation or enforcement hereof or of any such
document, that it is not subject thereto or that such action, suit or proceeding
may not be brought or is not maintainable in said courts or that the venue
thereof may not be appropriate or that this Agreement, the Merger Agreement, or
any such document may not be enforced in or by such courts, and the parties
hereto irrevocably agree that all claims with respect to such action or
proceeding shall be heard and determined in such a New York State or Federal
court. The parties hereby consent to and grant any such court jurisdiction over
the person of such parties and over the subject matter of such dispute and agree
that mailing of process or other papers in connection with any such action or
proceeding in the manner provided in Section 12 or in such other manner as may
be permitted by law, shall be valid and sufficient service thereof.
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY
WHICH MAY ARISE UNDER THIS AGREEMENT, THE COMPOUND AGREEMENT, THE STOCK OPTION
AGREEMENT OR THE VOTING AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT,
THE MERGER AGREEMENT, THE OTHER DOCUMENTS REFERRED TO IN THIS AGREEMENT AND THE
MERGER AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY
CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY
OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH
SUCH PARTY
-12-
<PAGE>
UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH
PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 11.
12. Notices. Any notice, request, instruction or other
document to be given hereunder by any party to the others shall be in writing
and delivered personally or sent by registered or certified mail, postage
prepaid, or by facsimile:
if to the Grantee:
Richard T. Collier
Pharmacia & Upjohn, Inc.
95 Corporate Drive
Bridgewater, NJ 08807
fax: (908) 306-4489
with copies to:
Neil T. Anderson
Matthew G. Hurd
Morgan N. Neuwirth
Martin J. Travers
Sullivan & Cromwell
125 Broad Street
New York, NY 10004
fax: (212) 558-3588
if to the Grantor:
Bruce E. MacMillan
SUGEN, Inc.
230 East Grand Avenue
South San Francisco, CA 94080
fax: (650) 553-8342
-13-
<PAGE>
with copies to:
Alan C. Mendelson
Suzanne Sawochka Hooper
Gianna M. Bosko
Cooley Godward LLP
5 Palo Alto Square
3000 El Camino Real
Palo Alto, California 94306
fax: (650) 857-0663
or to such other persons or addresses as may be designated in writing by the
party to receive such notice as provided above.
13. Entire Agreement. This Agreement (including any exhibits
and schedules hereto), the Merger Agreement and the other documents referred to
in this Agreement and the Merger Agreement, constitute the entire agreement, and
supersede all other prior agreements, understandings, representations and
warranties both written and oral, among the parties, with respect to the subject
matter hereof.
14. No Third Party Beneficiaries. This Agreement is not
intended to confer upon any person or entity other than the parties hereto any
rights or remedies hereunder.
15. Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall
not affect the validity or enforceability of the other provisions hereof. If any
provision of this Agreement, or the application thereof to any person or entity
or any circumstance, is invalid or unenforceable, (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other persons or entities or circumstances shall not be affected by
such invalidity or unenforceability, nor shall such invalidity or
unenforceability affect the validity or enforceability of such provision, or the
application thereof, in any other jurisdiction.
16. Specific Performance. The parties hereto each acknowledge
that, in view of the uniqueness of the subject matter hereof, the parties hereto
would not have an
-14-
<PAGE>
adequate remedy at law for money damages if this Agreement were not performed in
accordance with its terms, and therefore agree that the parties hereto shall be
entitled to specific enforcement of the terms hereof in addition to any other
remedy to which the parties hereto may be entitled at law or in equity.
17. Assignment. This Agreement shall not be assignable by
operation of law or otherwise; provided, however, that the Grantee may assign
its rights and obligations under this Agreement to any of its direct or indirect
wholly owned subsidiaries (including Merger Sub). Any purported assignment made
in contravention of this Agreement shall be null and void.
18. Captions. The Section captions herein are for convenience
of reference only and do not constitute part of this Agreement and shall not be
deemed to limit or otherwise affect any of the provisions hereof.
19. Termination. (a) The right to exercise the Option granted
pursuant to this Agreement shall terminate at (and the Option shall no longer be
exercisable after) the earliest of (i) the Effective Time (as defined in the
Merger Agreement), (ii) the first anniversary of the earliest to occur of the
events set forth in any of clauses (i), (ii), (iii) or (iv) of Section 2(d), and
(iii) the fifteenth day following the termination of the Merger Agreement if
prior to such fifteenth day the events set forth in any of clauses (i), (ii),
(iii) or (iv) of Section 2(d) shall not have occurred (such earliest date being
referred to in this Agreement as the "Termination Date"); provided that, if the
Option cannot be exercised or the Shares cannot be delivered to the Grantee upon
such exercise because one or more of the conditions set forth in Section 2(a) or
(b) hereof have not yet been satisfied, the Termination Date shall be extended
until thirty days after such impediment to exercise or delivery has been
removed.
(b) All representations and warranties contained in this
Agreement shall survive delivery of and payment for the Shares.
20. Profit Limitation. Notwithstanding any other provision of
this Agreement or the Merger Agreement, any Cancellation Amount shall be reduced
(but not below zero) to the extent necessary so that the sum of the portion of
any
-15-
<PAGE>
termination fee described in Section 8.5(b) of the Merger Agreement actually
paid to the Grantee (such portion actually paid, the "Termination Fee"), the
aggregate of all Cancellation Amounts paid to Grantee pursuant to this Agreement
and the cash proceeds actually received by the Grantee as the result of selling
Shares to a third party which acquires more than 50% of the Grantor's
outstanding voting securities (other than the Company or any of its affiliates)
shall not exceed $21,900,000. In no event shall (i) the sum of the aggregate
Cancellation Amounts paid to Grantee pursuant to this Agreement and the cash
proceeds actually received by the Grantee as the result of selling Shares to a
third party which acquires more than 50% of the Grantor's outstanding voting
securities (other than the Company or any of its affiliates) exceed $21,900,000,
or (ii) the sum of the Termination Fee, the aggregate Cancellation Amounts paid
to Grantee pursuant to this Agreement and the cash proceeds actually received by
the Grantee as the result of selling Shares to a third party which acquires more
than 50% of the Grantor's outstanding voting securities (other than the Company
or any of its affiliates) exceed $21,900,000.
-16-
<PAGE>
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by duly authorized officers of the parties hereto as of the date
hereof.
SUGEN, INC.
By: /s/ Stephen Evans-Freke
---------------------------------
Name: Stephen Evans-Freke
Title: Chairman of the Board and
Chief Executive Officer
PHARMACIA & UPJOHN, INC.
By: /s/ Christopher J. Coughlin
---------------------------------
Name: Christopher J. Coughlin
Title: Executive Vice President
UNIVERSITY ACQUISITION CORP.
By: /s/ Mats Petterson
---------------------------------
Name: Mats Petterson
Title: Senior Vice President
-17-
EXHIBIT 99.1
Pharmacia & Upjohn to Acquire SUGEN, Inc.
Strategic Acquisition Strengthens Drug Discovery Capabilities and
Oncology Portfolio
BRIDGEWATER, N.J. and SOUTH SAN FRANCISCO, Calif.--(BWHealthWire) --June 15,
1999--Pharmacia & Upjohn, Inc. (NYSE: PNU - news) and SUGEN (NASDAQ:SUGN - news)
today announced the signing of an agreement under which Pharmacia & Upjohn will
acquire complete ownership of SUGEN, a biotechnology company and worldwide
leader in target-driven drug discovery and development for novel
development-stage cancer therapies.
Under the terms of the agreement which is valued at approximately $650 million
on a net basis, each of approximately 23.5 million shares of SUGEN stock will be
exchanged for approximately $31 worth of Pharmacia & Upjohn stock, so long as
the price of Pharmacia & Upjohn stock is between $60.16 and $49.22 at the close
of the transaction. In no event will SUGEN stockholders receive less than .515
share of Pharmacia & Upjohn common stock, nor more than .630 share of Pharmacia
& Upjohn stock for each share of SUGEN common stock. The exact exchange ratio
will be based on the average price of Pharmacia & Upjohn stock prior to closing.
The transaction will be accounted for as a pooling of interests and will qualify
as a tax-free exchange. The transaction has received the approval of the Boards
of Directors of both Pharmacia & Upjohn and SUGEN and is subject to the approval
by SUGEN's stockholders and other customary regulatory approvals. Under certain
circumstances, if the merger agreement is terminated, Pharmacia & Upjohn has the
right to purchase up to 19.9% of SUGEN's common stock and has the right to a fee
of $17 million.
"SUGEN's target-driven approach to drug discovery and development is supported
by an outstanding scientific team and proprietary technology that we can
leverage across our company's core research areas," said Fred Hassan, Chief
Executive Officer, Pharmacia & Upjohn. "In addition to enhancing our
genomics-based drug discovery capabilities, this acquisition strengthens our
oncology portfolio by providing us with new therapeutic approaches to the
treatment of cancer. We are already in cytotoxics, hormonals and adjuvant
therapies. With the addition of the cytostatic platform represented by SUGEN, we
position P&U to become the new challenger in the oncology category."
Hassan added: "The acquisition of SUGEN is yet another example of the new P&U's
strategy to supplement our internal R&D initiatives with external innovation."
Stephen Evans-Freke, Chairman and Chief Executive Officer of SUGEN, said, "This
agreement with Pharmacia & Upjohn provides SUGEN with the resources, critical
mass and global infrastructure to commercialize the cancer drug candidates in
our pipeline far more rapidly than we could achieve on our own. It will also
enable us to apply our unique capabilities to other important disease areas in
which our efforts to date have been severely resource constrained."
The key to SUGEN's approach to drug discovery is its broad and proprietary
expertise in identifying cell signaling targets known as kinases and
phosphatases. These molecules are needed for normal signaling to occur between
and within cells. Abnormal signaling can affect cell growth and division and can
result in cancer and other diseases. SUGEN is a leader in developing new
therapeutic approaches to these diseases through its development of small
molecule inhibitors that regulate particular signaling pathways.
<PAGE>
SUGEN currently has three anti-cancer drugs in clinical development including
novel cytostatic agents and angiogenesis inhibitors. In addition to its current
focus in oncology, SUGEN is applying its technology platform to identify and
validate novel targets for a range of potential clinical applications.
"SUGEN's outstanding team of scientists has built a substantial technology
platform including an impressive intellectual property portfolio,
state-of-the-art genomics and bioinformatics, a large portfolio of novel targets
and novel chemistries and a growing pipeline of candidates that will add
immediate value to our research and development program," said Goran Ando, M.D.,
Pharmacia & Upjohn Executive Vice President and President, Research and
Development. "Our respective research organizations have complementary strengths
that provide us with an opportunity to achieve significant synergies and to
build competitive advantage."
SUGEN will remain based at its current headquarters in South San Francisco.
Peter Hirth, SUGEN's current Executive Vice President and Chairman R&D
Committee, will become President of SUGEN and will report to Ando. A merger
integration team consisting of senior management representatives of Pharmacia &
Upjohn and SUGEN has been appointed to oversee the successful integration of
SUGEN with Pharmacia & Upjohn.
The company estimates that the transaction will have a 1-2% dilutive impact on
earnings-per-share next year and is expected to be neutral in an 18-24 month
period. Said Hassan, "The SUGEN acquisition is an important investment in
sustaining P&U's long-term growth. Our previously-stated goal of annual
double-digit earnings growth remains unchanged."
Pharmacia & Upjohn is a global, innovation-driven pharmaceutical and healthcare
company. Pharmacia & Upjohn's products, services and employees demonstrate its
commitment to improving wellness and quality of life for people around the
world.
